



QUARTERLY STATEMENT
AS OF MARCH 31, 2026
OF THE CONDITION AND AFFAIRS OF THE
ESSENCE HEALTHCARE, INC.

NAIC Group Code..... 4597..... 4597..... NAIC Company Code..... 11699..... Employer's ID Number.... 20-8185682.....
(Current) (Prior)

Organized under the Laws of..... MO..... State of Domicile or Port of Entry..... MO.....
Country of Domicile..... US.....
Licensed as business type:..... Health Maintenance Organization..... Is HMO Federally Qualified?..... NO.....
Incorporated/Organized..... 01/30/2003..... Commenced Business..... 07/01/2004.....
Statutory Home Office..... 13900 Riverport Drive..... St. Louis, MO, US 63043.....
Main Administrative Office..... 13900 Riverport Drive.....
St. Louis, MO, US 63043..... 1-866-509-5398.....
(Telephone Number)
Mail Address..... 13900 Riverport Drive..... St. Louis, MO, US 63043.....
Primary Location of Books and
Records..... 13900 Riverport Drive.....
St. Louis, MO, US 63043..... 1-866-509-5398.....
(Telephone Number)
Internet Website Address..... www.essencehealthcare.com.....
Statutory Statement Contact..... Lisa Michelle McGinnis..... 636-544-1318.....
(Telephone Number)
lmcginnis@lumeris.com..... 314-222-7869.....
(E-Mail Address) (Fax Number)

OFFICERS

Jordan Reigel, President..... Erin Venable, Chief Financial Officer.....
Gail Halterman, Secretary.....

OTHER

Jason Siegel, Chief Actuary.....

DIRECTORS OR TRUSTEES

Richard Hardy Jones..... Martha Ellen Butler.....
Debbie Zimmerman.....
Vince Mellet..... Steve Udvarhelyi M.D.....

State of Missouri.....
County of Saint Louis..... SS


The officers of this reporting entity being duly sworn, each depose and say that they are the described officers of said reporting entity, and that on the reporting period stated above, all of the herein described assets were the absolute property of the said reporting entity, free and clear from any liens or claims thereon, except as herein stated, and that this statement, together with related exhibits, schedules and explanations therein contained, annexed or referred to, is a full and true statement of all the assets and liabilities and of the condition and affairs of the said reporting entity as of the reporting period stated above, and of its income and deductions therefrom for the period ended, and have been completed in accordance with the NAIC Annual Statement Instructions and Accounting Practices and Procedures manual except to the extent that: (1) state law may differ; or, (2) that state rules or regulations require differences in reporting not related to accounting practices and procedures, according to the best of their information, knowledge and belief, respectively. Furthermore, the scope of this attestation by the described officers also includes the related corresponding electronic filing with the NAIC, when required, that is an exact copy (except for formatting differences due to electronic filing) of the enclosed statement. The electronic filing may be requested by various regulators in lieu of or in addition to the enclosed statement.

x J. Reigel x Gail Halterman x Erin Venable
Jordan Reigel Gail Halterman Erin Venable
President Secretary Chief Financial Officer

Subscribed and sworn to before me
this 14th day of
May, 2026

- a. Is this an original filing? Yes
b. If no:
1. State the amendment number: _____
2. Date filed: _____
3. Number of pages attached: _____

x Andrea Marie D'Angelo



ASSETS

	Current Statement Date			4 December 31 Prior Year Net Admitted Assets
	1 Assets	2 Nonadmitted Assets	3 Net Admitted Assets (Cols. 1 - 2)	
1. Bonds	69,015,585		69,015,585	68,883,719
2. Stocks:				
2.1 Preferred stocks				
2.2 Common stocks	24,226,750	3,940,894	20,285,856	21,496,235
3. Mortgage loans on real estate:				
3.1 First liens				
3.2 Other than first liens				
4. Real estate:				
4.1 Properties occupied by the company (less \$..... encumbrances)				
4.2 Properties held for the production of income (less \$..... encumbrances)				
4.3 Properties held for sale (less \$..... encumbrances)				
5. Cash (\$.....43,179,423), cash equivalents (\$.....5,508,826) and short-term investments (\$.....0)	48,688,249		48,688,249	43,831,786
6. Contract loans (including \$..... premium notes)				
7. Derivatives				
8. Other invested assets				
9. Receivables for securities	-		-	
10. Securities lending reinvested collateral assets				
11. Aggregate write-ins for invested assets				
12. Subtotals, cash and invested assets (Lines 1 to 11)	141,930,584	3,940,894	137,989,690	134,211,740
13. Title plants less \$..... charged off (for Title insurers only)				
14. Investment income due and accrued	390,338		390,338	410,967
15. Premiums and considerations:				
15.1 Uncollected premiums and agents' balances in the course of collection	96,420	89	96,331	42,308
15.2 Deferred premiums, agents' balances and installments booked but deferred and not yet due (including \$..... earned but unbilled premiums)				
15.3 Accrued retrospective premiums (\$.....13,017,931) and contracts subject to redetermination (\$.....)	13,017,931		13,017,931	2,852,149
16. Reinsurance:				
16.1 Amounts recoverable from reinsurers	78,840		78,840	152,605
16.2 Funds held by or deposited with reinsured companies	4,048,563		4,048,563	4,773,289
16.3 Other amounts receivable under reinsurance contracts				
17. Amounts receivable relating to uninsured plans	16,079,264		16,079,264	20,166,875
18.1 Current federal and foreign income tax recoverable and interest thereon				374,512
18.2 Net deferred tax asset	4,172,270	368,420	3,803,850	4,138,347
19. Guaranty funds receivable or on deposit				
20. Electronic data processing equipment and software				
21. Furniture and equipment, including health care delivery assets (\$.....)				
22. Net adjustment in assets and liabilities due to foreign exchange rates				
23. Receivables from parent, subsidiaries and affiliates	1,651		1,651	1,220
24. Health care (\$.....) and other amounts receivable	43,227,685	9,931,785	33,295,900	31,758,333
25. Aggregate write-ins for other-than-invested assets	76,344	76,344	-	131,957
26. Total assets excluding Separate Accounts, Segregated Accounts and Protected Cell Accounts (Lines 12 to 25)	223,119,890	14,317,532	208,802,358	199,014,302
27. From Separate Accounts, Segregated Accounts and Protected Cell Accounts				
28. Total (Lines 26 and 27)	223,119,890	14,317,532	208,802,358	199,014,302
Details of Write-Ins				
1101.				
1102.				
1103.				
1198. Summary of remaining write-ins for Line 11 from overflow page				
1199. Totals (Lines 1101 through 1103 plus 1198) (Line 11 above)				
2501. Prepays	76,344	76,344	-	-
2502. Other Receivables				-
2503. State Tax Receivable				131,957
2598. Summary of remaining write-ins for Line 25 from overflow page				
2599. Totals (Lines 2501 through 2503 plus 2598) (Line 25 above)	76,344	76,344	-	131,957

LIABILITIES, CAPITAL AND SURPLUS

	Current Period			Prior Year
	1 Covered	2 Uncovered	3 Total	4 Total
1. Claims unpaid (less \$.....20,680,660 reinsurance ceded)	35,801,331		35,801,331	30,845,930
2. Accrued medical incentive pool and bonus amounts	21,223,021		21,223,021	19,040,912
3. Unpaid claims adjustment expenses	1,236,209		1,236,209	1,014,190
4. Aggregate health policy reserves, including the liability of \$..... for medical loss ratio rebate per the Public Health Service Act	1,400,000		1,400,000	1,400,000
5. Aggregate life policy reserves				
6. Property/casualty unearned premium reserve				
7. Aggregate health claim reserves				
8. Premiums received in advance	45,992		45,992	35,114
9. General expenses due or accrued	6,825,049		6,825,049	6,331,437
10.1 Current federal and foreign income tax payable and interest thereon (including \$..... on realized gains (losses))				
10.2 Net deferred tax liability				
11. Ceded reinsurance premiums payable				
12. Amounts withheld or retained for the account of others	824,067		824,067	494,997
13. Remittances and items not allocated				
14. Borrowed money (including \$..... current) and interest thereon \$..... (including \$..... current)				
15. Amounts due to parent, subsidiaries and affiliates	12,253,888		12,253,888	15,558,739
16. Derivatives				
17. Payable for securities				
18. Payable for securities lending				
19. Funds held under reinsurance treaties (with \$.....24,729,223 authorized reinsurers, \$..... unauthorized reinsurers and \$..... certified reinsurers)	24,729,223		24,729,223	21,979,957
20. Reinsurance in unauthorized and certified (\$.....) companies				
21. Net adjustments in assets and liabilities due to foreign exchange rates				
22. Liability for amounts held under uninsured plans	273,558		273,558	2,034,447
23. Aggregate write-ins for other liabilities (including \$..... current)	57,931		57,931	111,563
24. Total liabilities (Lines 1 to 23)	104,670,269		104,670,269	98,847,286
25. Aggregate write-ins for special surplus funds	XXX	XXX		
26. Common capital stock	XXX	XXX	100	100
27. Preferred capital stock	XXX	XXX		
28. Gross paid in and contributed surplus	XXX	XXX	46,224,787	46,224,787
29. Surplus notes	XXX	XXX		
30. Aggregate write-ins for other-than-special surplus funds	XXX	XXX		
31. Unassigned funds (surplus)	XXX	XXX	57,907,203	53,942,129
32. Less treasury stock, at cost:				
32.1 shares common (value included in Line 26 \$.....)	XXX	XXX		
32.2 shares preferred (value included in Line 27 \$.....)	XXX	XXX		
33. Total capital and surplus (Lines 25 to 31 minus Line 32)	XXX	XXX	104,132,090	100,167,016
34. Total liabilities, capital and surplus (Lines 24 and 33)	XXX	XXX	208,802,359	199,014,302
Details of Write-Ins				
2301. Unclaimed Property	57,931		57,931	111,563
2302.				
2303.				
2398. Summary of remaining write-ins for Line 23 from overflow page				
2399. Totals (Lines 2301 through 2303 plus 2398) (Line 23 above)	57,931		57,931	111,563
2501.	XXX	XXX		
2502.	XXX	XXX		
2503.	XXX	XXX		
2598. Summary of remaining write-ins for Line 25 from overflow page	XXX	XXX		
2599. Totals (Lines 2501 through 2503 plus 2598) (Line 25 above)	XXX	XXX		
3001.	XXX	XXX		
3002.	XXX	XXX		
3003.	XXX	XXX		
3098. Summary of remaining write-ins for Line 30 from overflow page	XXX	XXX		
3099. Totals (Lines 3001 through 3003 plus 3098) (Line 30 above)	XXX	XXX		

STATEMENT OF REVENUE AND EXPENSES

	Current Year to Date		Prior Year To Date	Prior Year Ended December 31
	1	2	3	4
	Uncovered	Total	Total	Total
1. Member Months	XXX	150,469	130,910	508,682
2. Net premium income (including \$..... non-health premium income)	XXX	139,256,792	125,426,703	450,908,068
3. Change in unearned premium reserves and reserve for rate credits	XXX			
4. Fee-for-service (net of \$..... medical expenses)	XXX			
5. Risk revenue	XXX			
6. Aggregate write-ins for other health care related revenues	XXX			
7. Aggregate write-ins for other non-health revenues	XXX			
8. Total revenues (Lines 2 to 7)	XXX	139,256,792	125,426,703	450,908,068
Hospital and Medical:				
9. Hospital/medical benefits		118,140,614	35,967,056	404,479,067
10. Other professional services		9,410,722	8,904,719	36,726,305
11. Outside referrals		9,066,584	9,972,412	41,585,454
12. Emergency room and out-of-area		3,502,283	3,112,376	11,518,526
13. Prescription drugs		34,789,763	23,831,565	99,130,626
14. Aggregate write-ins for other hospital and medical				
15. Incentive pool, withhold adjustments and bonus amounts		8,381,582	14,441,776	31,753,564
16. Subtotal (Lines 9 to 15)		183,291,548	96,229,904	625,193,542
Less:				
17. Net reinsurance recoveries		73,272,675	151,707	250,221,293
18. Total hospital and medical (Lines 16 minus 17)		110,018,873	96,078,197	374,972,249
19. Non-health claims (net)				
20. Claims adjustment expenses, including \$.....54,907 cost containment expenses		979,331	7,335,172	3,017,689
21. General administrative expenses		20,834,717	15,701,159	60,496,026
22. Increase in reserves for life and accident and health contracts (including \$..... increase in reserves for life only)				
23. Total underwriting deductions (Lines 18 through 22)		131,832,921	119,114,528	438,485,964
24. Net underwriting gain or (loss) (Lines 8 minus 23)	XXX	7,423,871	6,312,175	12,422,104
25. Net investment income earned		2,133,353	926,583	3,398,341
26. Net realized capital gains (losses) less capital gains tax of \$.....		(12,531)	(518,709)	(992,759)
27. Net investment gains (losses) (Lines 25 plus 26)		2,120,822	407,874	2,405,582
28. Net gain or (loss) from agents' or premium balances charged off [(amount recovered \$.....) (amount charged off \$.....71,737)]		(25,886)	(56,755)	21,627
29. Aggregate write-ins for other income or expenses				
30. Net income or (loss) after capital gains tax and before all other federal income taxes (Lines 24 plus 27 plus 28 plus 29)	XXX	9,518,807	6,663,294	14,849,313
31. Federal and foreign income taxes incurred	XXX	3,135,606	-	1,817,377
32. Net income (loss) (Lines 30 minus 31)	XXX	6,383,201	6,663,294	13,031,936
Details of Write-Ins				
0601.	XXX			
0602.	XXX			
0603.	XXX			
0698. Summary of remaining write-ins for Line 6 from overflow page	XXX			
0699. Totals (Lines 0601 through 0603 plus 0698) (Line 6 above)	XXX			
0701.	XXX			
0702.	XXX			
0703.	XXX			
0798. Summary of remaining write-ins for Line 7 from overflow page	XXX			
0799. Totals (Lines 0701 through 0703 plus 0798) (Line 7 above)	XXX			
1401.				
1402.				
1403.				
1498. Summary of remaining write-ins for Line 14 from overflow page				
1499. Totals (Lines 1401 through 1403 plus 1498) (Line 14 above)				
2901.				
2902.				
2903.				
2998. Summary of remaining write-ins for Line 29 from overflow page				
2999. Totals (Lines 2901 through 2903 plus 2998) (Line 29 above)				

STATEMENT OF REVENUE AND EXPENSES (CONTINUED)

	1	2	3
	Current Year To Date	Prior Year To Date	Prior Year Ended December 31
CAPITAL & SURPLUS ACCOUNT			
33. Capital and surplus prior reporting year.....	100,167,014	99,416,728	99,416,728
34. Net income or (loss) from Line 32.....	6,383,201	6,663,294	13,031,936
35. Change in valuation basis of aggregate policy and claim reserves.....			
36. Change in net unrealized capital gains (losses) less capital gains tax of \$.....	(2,551,992)	(202,790)	(5,379,675)
37. Change in net unrealized foreign exchange capital gain or (loss).....			
38. Change in net deferred income tax.....	(331,865)	1,265,253	438,609
39. Change in nonadmitted assets.....	988,496	(12,540,736)	(6,132,059)
40. Change in unauthorized and certified reinsurance.....			
41. Change in treasury stock.....			
42. Change in surplus notes.....			
43. Cumulative effect of changes in accounting principles.....			
44. Capital Changes:			
44.1 Paid in.....			
44.2 Transferred from surplus (stock dividend).....			
44.3 Transferred to surplus.....			
45. Surplus adjustments:			
45.1 Paid in.....	-	-	-
45.2 Transferred to capital (stock dividend).....			
45.3 Transferred from capital.....			
46. Dividends to stockholders.....			
47. Aggregate write-ins for gains or (losses) in surplus.....	(522,763)	-	(1,208,525)
48. Net change in capital and surplus (Lines 34 to 47).....	3,965,077	(4,814,979)	750,286
49. Capital and surplus end of reporting period (Line 33 plus 48).....	104,132,091	94,601,749	100,167,014
Details of Write-Ins			
4701. Other.....	(522,763)		(1,208,525)
4702.....			
4703.....			
4798. Summary of remaining write-ins for Line 47 from overflow page.....			
4799. Totals (Lines 4701 through 4703 plus 4798) (Line 47 above).....	(522,763)	-	(1,208,525)

CASH FLOW

	1	2	3
	Current Year To Date	Prior Year To Date	Prior Year Ended December 31
Cash from Operations			
1. Premiums collected net of reinsurance	129,109,129	117,035,335	451,749,286
2. Net investment income	2,171,592	1,166,564	3,712,682
3. Miscellaneous income	(392,187)	(4,265,837)	6,412,554
4. Total (Lines 1 to 3)	130,888,534	113,936,062	461,874,522
5. Benefit and loss related payments	102,807,598	109,020,273	410,835,540
6. Net transfers to Separate Accounts, Segregated Accounts and Protected Cell Accounts			
7. Commissions, expenses paid and aggregate write-ins for deductions	20,148,206	22,157,266	73,410,355
8. Dividends paid to policyholders			
9. Federal and foreign income taxes paid (recovered) net of \$..... tax on capital gains (losses)	2,761,094	-	2,191,889
10. Total (Lines 5 through 9)	125,716,898	131,177,539	486,437,784
11. Net cash from operations (Line 4 minus Line 10)	5,171,636	(17,241,477)	(24,563,262)
Cash from Investments			
12. Proceeds from investments sold, matured or repaid:			
12.1 Bonds	529,795	19,397,427	37,959,422
12.2 Stocks			
12.3 Mortgage loans			
12.4 Real estate			
12.5 Other invested assets			
12.6 Net gains or (losses) on cash, cash equivalents and short-term investments			
12.7 Miscellaneous proceeds	-	-	-
12.8 Total investment proceeds (Lines 12.1 to 12.7)	529,795	19,397,427	37,959,422
13. Cost of investments acquired (long-term only):			
13.1 Bonds	682,792		
13.2 Stocks			
13.3 Mortgage loans			
13.4 Real estate			
13.5 Other invested assets			
13.6 Miscellaneous applications	-	-	-
13.7 Total investments acquired (Lines 13.1 to 13.6)	682,792	-	-
14. Net increase/(decrease) in contract loans and premium notes			
15. Net cash from investments (Line 12.8 minus Line 13.7 and Line 14)	(152,997)	19,397,427	37,959,422
Cash from Financing and Miscellaneous Sources			
16. Cash provided (applied):			
16.1 Surplus notes, capital notes			
16.2 Capital and paid in surplus, less treasury stock	-	-	-
16.3 Borrowed funds			
16.4 Net deposits on deposit-type contracts and other insurance liabilities			
16.5 Dividends to stockholders			
16.6 Other cash provided (applied)	(162,174)	9,072,381	27,785,960
17. Net cash from financing and miscellaneous sources (Line 16.1 through Line 16.4 minus Line 16.5 plus Line 16.6)	(162,174)	9,072,381	27,785,960
Reconciliation of Cash, Cash Equivalents and Short-Term Investments			
18. Net change in cash, cash equivalents and short-term investments (Line 11, plus Lines 15 and 17)	4,856,465	11,228,331	41,182,120
19. Cash, cash equivalents and short-term investments:			
19.1 Beginning of year	43,831,784	2,649,663	2,649,664
19.2 End of period (Line 18 plus Line 19.1)	48,688,249	13,877,994	43,831,784
Note: Supplemental disclosures of cash flow information for non-cash transactions:			
20.0001. Capital contributions			

EXHIBIT OF PREMIUMS, ENROLLMENT AND UTILIZATION

	1	Comprehensive (Hospital & Medical)		4	5	6	7	8	9	10	11	12	13	14
	Total	2 Individual	3 Group	Medicare Supplement	Vision Only	Dental Only	Federal Employees Health Benefits Plan	Title XVIII Medicare	Title XIX Medicaid	Credit A&H	Disability Income	Long-Term Care	Other Health	Other Non- Health
Total Members at end of:														
1. Prior year.....	41,369							41,369						
2. First quarter.....	50,277							50,277						
3. Second quarter.....														
4. Third quarter.....														
5. Current year.....														
6. Current year member months.....	150,469							150,469						
Total Member Ambulatory Encounters for Period:														
7. Physician.....	80,653							80,653						
8. Non-physician.....	36,642							36,642						
9. Total.....	117,295							117,295						
10. Hospital patient days incurred.....	10,408							10,408						
11. Number of inpatient admissions.....	1,929							1,929						
12. Health premiums written (a).....	220,349,212							220,349,212						
13. Life premiums direct.....														
14. Property/casualty premiums written.....														
15. Health premiums earned.....	220,349,212							220,349,212						
16. Property/casualty premiums earned.....														
17. Amount paid for provision of health care services.....	177,039,840							177,039,840						
18. Amount incurred for provision of health care services.....	183,291,549							183,291,549						

(a) For health premiums written: amount of Medicare Title XVIII exempt from state taxes or fees \$220,349,212

CLAIMS UNPAID AND INCENTIVE POOL, WITHHOLD AND BONUS (REPORTED AND UNREPORTED)

Aging Analysis of Unpaid Claims

1 Account	2 1 - 30 Days	3 31 - 60 Days	4 61 - 90 Days	5 91 - 120 Days	6 Over 120 Days	7 Total
Claims Unpaid (Reported)						
0399999 – Aggregate accounts not individually listed-covered	1,261,382					1,261,382
0499999 – Subtotals	1,261,382					1,261,382
0599999 – Unreported claims and other claim reserves						55,220,609
0799999 – Total claims unpaid						56,481,991
0899999 – Accrued medical incentive pool and bonus amounts						21,223,021

UNDERWRITING AND INVESTMENT EXHIBIT
ANALYSIS OF CLAIMS UNPAID-PRIOR YEAR-NET OF REINSURANCE

Line of Business	Claims Paid Year to Date		Liability End of Current Quarter		5 Claims Incurred in Prior Years (Columns 1 + 3)	6 Estimated Claim Reserve and Claim Liability Dec. 31 of Prior Year
	1 On Claims Incurred Prior to January 1 of Current Year	2 On Claims Incurred During the Year	3 On Claims Unpaid Dec. 31 of Prior Year	4 On Claims Incurred During the Year		
1. Comprehensive (hospital and medical) individual.....						
2. Comprehensive (hospital and medical) group.....						
3. Medicare Supplement.....						
4. Vision only.....						
5. Dental only.....						
6. Federal Employees Health Benefits Plan.....						
7. Title XVIII – Medicare.....	28,024,458	69,543,233	2,613,147	33,188,184	30,637,605	30,845,929
8. Title XIX – Medicaid.....						
9. Credit A&H.....						
10. Disability income.....						
11. Long-term care.....						
12. Other health.....						
13. Health subtotal (Lines 1 to 12).....	28,024,458	69,543,233	2,613,147	33,188,184	30,637,605	30,845,929
14. Health care receivables (a).....	24,567,462	18,353,625			24,567,462	42,035,286
15. Other non-health.....						
16. Medical incentive pools and bonus amounts.....	6,199,473	–	15,069,188	6,153,833	21,268,661	19,040,912
17. Totals (Lines 13-14+15+16).....	9,656,469	51,189,608	17,682,335	39,342,017	27,338,804	7,851,555

(a) Excludes \$ loans or advances to providers not yet expensed.

Notes to the Financial Statements

1. Summary of Significant Accounting Policies and Going Concern

A. Accounting Practices

The financial statements of Essence Healthcare, Inc. ("EHI" or "the Company"), a 4-5 star health plan as rated by the Centers for Medicare and Medicaid Services (CMS), are presented on the basis of accounting practices prescribed or permitted by the Missouri Department of Insurance (the Department). The Missouri Department of Insurance recognizes only statutory accounting practices prescribed or permitted by the State of Missouri for determining and reporting the financial condition and results of operations of an insurance company, to determine its solvency under the Missouri Department of Insurance Law. The National Association of Insurance Commissioners' (NAIC) Accounting Practices and Procedures manual, (NAIC SAP) has been adopted as a component of prescribed or permitted practices by the State of Missouri.

A reconciliation of the Company's net income and capital and surplus between NAIC SAP and practices prescribed and permitted by the state of Missouri is shown below:

	SSAP #	F/S Page	F/S Line #	03/31/2026	12/31/2025
Net Income					
(1) State basis (Page 4, Line 32, Columns 2 & 4)	XXX	XXX	XXX	\$ 6,383,201	\$ 13,031,936
(2) State prescribed practices that are an increase / (decrease) from NAIC SAP:					
(3) State permitted practices that are an increase / (decrease) from NAIC SAP:					
(4) NAIC SAP (1-2-3=4)	XXX	XXX	XXX	<u>\$ 6,383,201</u>	<u>\$ 13,031,936</u>
Surplus					
(5) State basis (Page 3, Line 33, Columns 3 & 4)	XXX	XXX	XXX	\$ 104,132,090	\$ 100,167,016
(6) State prescribed practices that are an increase / (decrease) from NAIC SAP:					
Furniture and equipment, including health care delivery assets	19	2	21		
(7) State permitted practices that are an increase / (decrease) from NAIC SAP:					
(8) NAIC SAP (5-6-7=8)	XXX	XXX	XXX	<u>\$ 104,132,090</u>	<u>\$ 100,167,016</u>

B. Use of Estimates in the Preparation of the Financial Statements - No Significant Changes

C. Accounting Policy

Premium revenues are recognized in the period in which the eligible individuals are entitled to receive healthcare services. The monthly Part C and Part D premium revenue received from CMS is subject to retrospective adjustment based on the level of care required by members and the hierarchical condition categories (HCC) established by CMS. CMS uses HCC in order to promote fair payments under the Medicare Advantage program so as to direct payments to entities that reward efficiency and encourage excellent care for the chronically ill. The ultimate amount of the retrospective adjustment is influenced by several factors, including the relative acuity of illnesses experienced by members of the Company's plans as compared to those of other competing plans.

Under the Medicare Part D program, there are multiple separate elements of payment received by the Company during the plan year. These payment elements are as follows:

- CMS Premium – CMS pays a fixed monthly premium per member to the Company for the entire plan year.
- Member Premium – Additionally, certain members pay a fixed monthly premium to the Company for the entire plan year.
- Low-Income Premium Subsidy – For qualifying low-income members, CMS pays some or all of the member's monthly premium to the Company on the member's behalf.
- Catastrophic Reinsurance Subsidy – Effective January 2025, under the Inflation Reduction Act, CMS pays the Company a cost reimbursement estimate monthly to fund the CMS obligation to pay approximately 20% of brand drugs and 40% of generic drugs incurred by individual members in excess of the individual annual out-of-pocket maximum. In 2024, CMS was obligated to pay approximately 80% of incurred expenses by individual members in excess of the individual annual out-of-pocket maximum. A settlement is made with CMS based on actual cost experience, after the end of the plan year.
- Low-Income Member Cost Sharing Subsidy – For qualifying low-income members, CMS pays on the member's behalf some or all of a member's cost sharing amounts, such as deductibles and coinsurance. The cost sharing subsidy is funded by CMS through monthly payments to the Company. The Company administers and pays the subsidized portion of the claims on behalf of CMS, and a settlement payment is made between CMS and the Company based on actual claims and premium experience, after the end of the plan year.
- CMS Risk-Share – Premiums from CMS are subject to risk corridor provisions that compare costs targeted in the Company's annual bids by product and region to actual prescription drug costs, limited to actual costs that would have been incurred under the standard coverage as defined by CMS. Variances of more than 5% above or below the original bid submitted by the Company may result in CMS making additional payments to the Company or require the Company to refund to CMS a portion of the premiums it received. The Company estimates and recognizes an adjustment to premium revenues related to the risk corridor payment settlement based upon pharmacy claims experience. The estimate of the settlement associated with these risk corridor provisions requires the Company to consider factors that may not be certain, including member eligibility status differences with CMS and the timing of prescription drug event (PDE) reporting. The Company records risk-share adjustments to premium revenue in the statements of operations and aggregate health policy obligations and reserves in the statements of assets, liabilities, and capital and surplus.
- Coverage Gap Discount (CGD) – Members are provided a discount on brand name Part D prescription drugs in the coverage gap. This discount is funded by CMS and pharmaceutical manufacturers while the Company administers the application of these funds. Amounts received are not reflected as premium revenues, but rather are accounted for as deposits. The Company records a liability when amounts are received from CMS and a receivable when the amounts owed by manufacturers are known. This program was eliminated as of December 31, 2024 and replaced with the Manufacturer Discount Program.

Notes to the Financial Statements

1. Summary of Significant Accounting Policies and Going Concern (Continued)

- **Manufacturer Discount Program** - This program replaced the CGD and is effective January 1, 2025. Manufacturers are required to provide members mandatory discounts on certain covered drugs both below and above the annual out-of-pocket threshold. Under this program discounts are administered through CMS and its contracted third party administrator. Amounts received are not reflected as premium revenues, but rather are accounted for as deposits. The Company records a liability when amounts are received from CMS and a receivable when the amounts owed by manufacturers are known.
- **Medicare Prescription Payment Plan (M3P)** - This voluntary program was effective January 1, 2025 and allows Medicare Part D beneficiaries to elect to have out-of-pocket prescription drug costs paid by the Company at the point of sale and subsequently repaid in equal monthly installments over the remainder of the plan year. Amounts advanced on behalf of the members are recorded as accounts receivable and are periodically assessed for collectability.

The CMS Premium, the Member Premium, and the Low-Income Premium Subsidy represent payments for the Company's insurance risk coverage under the Medicare Parts C and D programs and therefore are recorded as Premium Revenue in the Statement of Revenue and Expenses. Premium revenue is recognized ratably over the period in which eligible individuals are entitled to receive prescription drug benefits. The Company records premium payments received in advance of the applicable service period in Unearned Revenues in the Statements of Assets, Liabilities, Capital and Surplus.

The Catastrophic Reinsurance Subsidy and Low-Income Member Cost Sharing Subsidy represent a cost reimbursement under the Medicare Part D program. Amounts received or owed for these subsidies are recorded as a liability or receivable in the Statements of Assets, Liabilities, Capital and Surplus.

Pharmacy benefit costs are expensed as incurred and are recognized in Medical and Hospital Expense in the Statements of Revenue and Expenses. Related administrative costs are reported in General Administrative Expenses in the Statements of Revenue and Expenses.

In addition, the Company uses the following accounting policies:

- (1) Short-term investments - No Significant Changes
- (2) Bonds are stated at amortized cost using the scientific interest method. The Company does not own any mandatory convertible securities or SVO-Identified bond ETFs reported on Schedule D-1
- (3) Common stocks - No Significant Changes
- (4) Preferred stocks - No Significant Changes
- (5) Mortgage loans - No Significant Changes
- (6) Loan-backed securities designated with a NAIC 1 or 2 are reported at amortized cost. Loan-backed securities with NAIC designations of 3 through 6 are reported at the lower of amortized cost or fair value. The retrospective adjustment method is used to value all securities, except for interest only securities or securities where the yield had become negative, that are valued using the prospective method.
- (7) In the first quarter of 2024, the Company made a surplus contribution of \$9,300,000 to Essence Healthcare PPO, Inc. In the second quarter of 2024 the Company made a surplus contribution of \$7,000,000 to Essence Healthcare PPO, Inc. In the third quarter of 2024, the Company made a surplus contribution of \$6,100,000 to Essence Healthcare PPO, Inc. In the fourth quarter of 2024, the Company made a surplus contribution of \$7,400,000 to Essence Healthcare PPO, Inc.
- (8) Investments in joint ventures, partnerships and limited liability companies - No Significant Changes
- (9) Derivatives - No Significant Changes
- (10) Investment income as a factor in the premium deficiency calculation - No Significant Changes
- (11) Liabilities for losses and loss/claim adjustment expenses - No Significant Changes
- (12) Changes in capitalization policy - No Significant Changes
- (13) Pharmaceutical rebate receivables - No Significant Changes

D. Going Concern

Management has evaluated the Company's ability to continue as a going concern. There is no substantial doubt in its ability to continue as a going concern.

2. Accounting Changes and Corrections of Errors - No Significant Changes

3. Business Combinations and Goodwill - No Significant Changes

4. Discontinued Operations - No Significant Changes

5. Investments

- A. Mortgage Loans, including Mezzanine Real Estate Loans - No Significant Changes
- B. Debt Restructuring - No Significant Changes
- C. Reverse Mortgages - No Significant Changes
- D. Asset-Backed Securities - None
- E. Dollar Repurchase Agreements and/or Securities Lending Transactions - None
- F. Repurchase Agreements Transactions Accounted for as Secured Borrowing - None

Notes to the Financial Statements

5. Investments (Continued)

- G. Reverse Repurchase Agreements Transactions Accounted for as Secured Borrowing - None
- H. Repurchase Agreements Transactions Accounted for as a Sale - None
- I. Reverse Repurchase Agreements Transactions Accounted for as a Sale - None
- J. Real Estate - No Significant Changes
- K. Investments in Tax Credit Structures (tax credit investments) - None
- L. Restricted Assets

(1) Restricted assets (including pledged)

Restricted Asset Category	(1) Total Gross (Admitted & Nonadmitted) Restricted from Current Year	(2) Total Gross (Admitted & Nonadmitted) Restricted from Prior Year	(3) Increase / (Decrease) (1 minus 2)	(4) Total Current Year Nonadmitted Restricted	(5) Total Current Year Admitted Restricted (1 minus 4)	(6) Gross (Admitted & Nonadmitted) Restricted to Total Assets	(7) Admitted Restricted to Total Admitted Assets	(8) Amount Reported in General Interrogatories	(9) Difference from Note and Annual GI	(10) Annual GI Ref
a. Subject to contractual obligation for which liability is not shown	\$	\$	\$	\$	\$	%	%	XXX	XXX	XXX
b. Collateral held under security lending agreements								XXX	XXX	25.04+25.05
c. Subject to repurchase agreements								XXX	XXX	26.21
d. Subject to reverse repurchase agreements								XXX	XXX	26.22
e. Subject to dollar repurchase agreements								XXX	XXX	26.23
f. Subject to dollar reverse repurchase agreements								XXX	XXX	26.24
g. Placed under option contracts								XXX	XXX	26.25
h. Letter stock or securities restricted as to sale - excluding FHLB capital stock								XXX	XXX	26.26
i. FHLB capital stock								XXX	XXX	26.27
j. On deposit with states	2,046,481	2,186,967	(140,486)		2,046,481	0.917	0.980	XXX	XXX	26.28
k. On deposit with other regulatory bodies								XXX	XXX	26.29
l. Pledged as collateral to FHLB (including assets backing funding agreements)								XXX	XXX	26.31
m. Pledged as collateral not captured in other categories								XXX	XXX	26.30
n. Other restricted assets								XXX	XXX	26.32
o. Collateral assets received and on balance sheet								XXX	XXX	XXX
p. Assets held under modco reinsurance agreements								XXX	XXX	XXX
q. Assets held under funds withheld reinsurance agreements								XXX	XXX	XXX
r. Total restricted assets (Sum of a through q)	\$ 2,046,481	\$ 2,186,967	\$ (140,486)	\$	\$ 2,046,481	0.917 %	0.980 %	XXX	XXX	XXX

- (2) Detail of assets pledged as collateral not captured in other categories (contracts that share similar characteristics, such as reinsurance (excluding Modco/FWH) and derivatives, are reported in the aggregate) - None
- (3) Detail of other restricted assets (contracts that share similar characteristics, such as reinsurance (excluding Modco/FWH) and derivatives, are reported in the aggregate) - None
- (4) Collateral received and assets held under Modco/Funds Withheld (FWH) reinsurance agreements reflected as assets within the reporting entity's financial statements - None
- (5) Assets held as collateral or under modified coinsurance (Modco) or funds withheld reinsurance (FWH) agreements that have been pledged for another purpose specific to the insurance reporting entity (not for the benefit of the reinsurer) - None

- M. Working Capital Finance Investments - None
- N. Offsetting and Netting of Assets and Liabilities - None
- O. 5GI Securities - No Significant Changes
- P. Short Sales - No Significant Changes
- Q. Prepayment Penalty and Acceleration Fees - No Significant Changes
- R. Reporting Entity's Share of Cash Pool by Asset Type - None
- S. Aggregate Collateral Loans by Qualifying Investment Collateral - None

6. Joint Ventures, Partnerships and Limited Liability Companies - No Significant Changes

7. Investment Income

- A. Due and Accrued Income Excluded from Surplus

All investment income due and accrued with amounts that are over 90 days past due with the exception of mortgage loans in default are excluded from surplus.

Notes to the Financial Statements

7. Investment Income (Continued)

- B. Total Amount Excluded - None
- C. The gross, nonadmitted and admitted amounts for interest income due and accrued

Interest Income Due and Accrued	Amount
1. Gross	\$ 390,338
2. Nonadmitted	\$
3. Admitted	\$ 390,338

- D. The aggregate deferred interest - None
- E. The cumulative amounts of paid-in-kind (PIK) interest included in the current principal balance - None

8. Derivative Instruments

- A. Derivatives under SSAP No. 86 - Derivatives - None
- B. Derivatives under SSAP No. 108 - Derivative Hedging Variable Annuity Guarantees (Life/Fraternal Only) - None

9. Income Taxes

- A. Components of the net deferred tax asset/(liability)

(1) Change between years by tax character

	03/31/2026			12/31/2025			Change		
	(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)
	Ordinary	Capital	Total (Col 1+2)	Ordinary	Capital	Total (Col 4+5)	Ordinary (Col 1-4)	Capital (Col 2-5)	Total (Col 7+8)
(a) Gross deferred tax assets	\$ 3,804,712	\$ 368,420	\$ 4,173,132	\$ 4,139,209	\$ 365,788	\$ 4,504,997	\$ (334,497)	\$ 2,632	\$ (331,865)
(b) Statutory valuation allowance adjustments									
(c) Adjusted gross deferred tax assets (1a - 1b)	3,804,712	368,420	4,173,132	4,139,209	365,788	4,504,997	(334,497)	2,632	(331,865)
(d) Deferred tax assets nonadmitted		368,420	368,420		365,788	365,788		2,632	2,632
(e) Subtotal net admitted deferred tax asset (1c - 1d)	\$ 3,804,712	\$ -	\$ 3,804,712	\$ 4,139,209	\$ -	\$ 4,139,209	\$ (334,497)	\$ -	\$ (334,497)
(f) Deferred tax liabilities	862		862	862		862	-		-
(g) Net admitted deferred tax asset/(net deferred tax liability) (1e - 1f)	\$ 3,803,850	\$ -	\$ 3,803,850	\$ 4,138,347	\$ -	\$ 4,138,347	\$ (334,497)	\$ -	\$ (334,497)

(2) Admission calculation components SSAP No. 101

	03/31/2026			12/31/2025			Change		
	(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)
	Ordinary	Capital	Total (Col 1+2)	Ordinary	Capital	Total (Col 4+5)	Ordinary (Col 1-4)	Capital (Col 2-5)	Total (Col 7+8)
(a) Federal income taxes paid in prior years recoverable through loss carrybacks									
(b) Adjusted gross deferred tax assets expected to be realized (excluding the amount of deferred tax assets from 2(a) above) after application of the threshold limitation (lesser of 2(b)1 and 2(b)2 below)	3,804,712		3,804,712	4,139,209		4,139,209	(334,497)		(334,497)
1. Adjusted gross deferred tax assets expected to be realized following the balance sheet date									
2. Adjusted gross deferred tax assets allowed per limitation threshold	XXX	XXX	15,048,680	XXX	XXX	9,540,342	XXX	XXX	5,508,338
(c) Adjusted gross deferred tax assets (excluding the amount of deferred tax assets from 2(a) and 2(b) above) offset by gross deferred tax liabilities									
(d) Deferred tax assets admitted as the result of application of SSAP No. 101. Total (2(a) + 2(b) + 2(c))	\$ 3,804,712	\$ -	\$ 3,804,712	\$ 4,139,209	\$ -	\$ 4,139,209	\$ (334,497)	\$ -	\$ (334,497)

(3) Ratio used as basis of admissibility

	03/31/2026	12/31/2025
(a) Ratio percentage used to determine recovery period and threshold limitation amount	496.530 %	295.760 %
(b) Amount of adjusted capital and surplus used to determine recovery period and threshold limitation in 2(b)2 above	\$ 100,324,534	\$ 95,403,417

Notes to the Financial Statements

9. Income Taxes (Continued)

(4) Impact of tax-planning strategies

(a) Determination of adjusted gross deferred tax assets and net admitted deferred tax assets, by tax character as a percentage

	03/31/2026		12/31/2025		Change	
	(1)	(2)	(3)	(4)	(5)	(6)
	Ordinary	Capital	Ordinary	Capital	Ordinary (Col. 1-3)	Capital (Col. 2-4)
1. Adjusted gross DTAs amount from Note 9A1(c)	\$ 3,804,712	\$ 368,420	\$ 4,139,209	\$ 365,788	\$ (334,497)	\$ 2,632
2. Percentage of adjusted gross DTAs by tax character attributable to the impact of tax planning strategies	%	%	%	%	%	%
3. Net admitted adjusted gross DTAs amount from Note 9A1(e)	\$ 3,804,712	\$ -	\$ 4,139,209	\$ -	\$ (334,497)	\$ -
4. Percentage of net admitted adjusted gross DTAs by tax character admitted because of the impact of tax planning strategies	%	%	%	%	%	%

(b) Use of reinsurance-related tax-planning strategies

Does the company's tax-planning strategies include the use of reinsurance? **NO**

B. Regarding deferred tax liabilities that are not recognized - None

C. Major components of current income taxes incurred

	(1)	(2)	(3)
	03/31/2026	12/31/2025	Change (1-2)
Current income taxes incurred consist of the following major components:			
1. Current Income Tax			
(a) Federal	\$ 3,135,606	\$ 1,817,776	\$ 1,317,830
(b) Foreign			
(c) Subtotal (1a+1b)	\$ 3,135,606	\$ 1,817,776	\$ 1,317,830
(d) Federal income tax on net capital gains			
(e) Utilization of capital loss carry-forwards			
(f) Other	-	(399)	399
(g) Federal and foreign income taxes incurred (1c+1d+1e+1f)	\$ 3,135,606	\$ 1,817,377	\$ 1,318,229
2. Deferred Tax Assets			
(a) Ordinary			
(1) Discounting of unpaid losses	\$ 219,774	\$ 173,359	\$ 46,415
(2) Unearned premium reserve	1,932	1,475	457
(3) Policyholder reserves			
(4) Investments			
(5) Deferred acquisition costs			
(6) Policyholder dividends accrual			
(7) Fixed assets			
(8) Compensation and benefits accrual			
(9) Pension accrual			
(10) Receivables - nonadmitted			
(11) Net operating loss carry-forward			
(12) Tax credit carry-forward			
(13) Other	3,583,006	3,964,375	(381,369)
(99) Subtotal (Sum of 2a1 through 2a13)	\$ 3,804,712	\$ 4,139,209	\$ (334,497)
(b) Statutory valuation allowance adjustment			
(c) Nonadmitted			
(d) Admitted ordinary deferred tax assets (2a99 - 2b - 2c)	\$ 3,804,712	\$ 4,139,209	\$ (334,497)
(e) Capital			
(1) Investments	\$ -	\$ -	\$ -
(2) Net capital loss carry-forward	368,420	365,788	2,632
(3) Real estate			
(4) Other			
(99) Subtotal (2e1+2e2+2e3+2e4)	\$ 368,420	\$ 365,788	\$ 2,632
(f) Statutory valuation allowance adjustment			
(g) Nonadmitted	368,420	365,788	2,632
(h) Admitted capital deferred tax assets (2e99 - 2f - 2g)	-	-	-
(i) Admitted deferred tax assets (2d + 2h)	\$ 3,804,712	\$ 4,139,209	\$ (334,497)

Notes to the Financial Statements

9. Income Taxes (Continued)

	(1) 03/31/2026	(2) 12/31/2025	(3) Change (1-2)
3. Deferred Tax Liabilities			
(a) Ordinary			
(1) Investments	\$ 862	\$ 862	\$ -
(2) Fixed assets			
(3) Deferred and uncollected premium			
(4) Policyholder reserves			
(5) Other			
(99) Subtotal (3a1+3a2+3a3+3a4+3a5)	<u>\$ 862</u>	<u>\$ 862</u>	<u>\$ -</u>
(b) Capital			
(1) Investments	\$	\$	\$
(2) Real estate			
(3) Other			
(99) Subtotal (3b1+3b2+3b3)	<u>\$</u>	<u>\$</u>	<u>\$</u>
(c) Deferred tax liabilities (3a99 + 3b99)	<u>\$ 862</u>	<u>\$ 862</u>	<u>\$ -</u>
4. Net deferred tax assets/liabilities (2i - 3c)	<u>\$ 3,803,850</u>	<u>\$ 4,138,347</u>	<u>\$ (334,497)</u>

The change in deferred income taxes is comprised of the following (this analysis is exclusive of nonadmitted assets as the Change in Nonadmitted Assets is reported separately from the Change in Net Deferred Income Taxes in the surplus section of the Annual Statement):

	Current Period	Prior Year	Change (Col. 1 - Col. 2)
Adjusted gross deferred tax assets	\$	\$	\$
Total deferred tax liabilities			
Net deferred tax assets (liabilities)	<u>\$</u>	<u>\$</u>	<u>\$</u>
Statutory valuation allowance adjustment			
Net deferred tax assets (liabilities) after statutory valuation allowance	<u>\$</u>	<u>\$</u>	<u>\$</u>
Tax effect of unrealized gains (losses)			
Change in net deferred income tax			<u><u>\$</u></u>

D. Among the more significant book to tax adjustments

The significant items causing a difference between the statutory Federal income tax rate and the Company's effective income tax rate at March 31, 2026 are as follows:

	03/31/2026	Effective Tax Rate
Income before (Federal) taxes	\$ 3,253,608	21.000 %
DRD deduction and tax-exempt interest, net		
Prior year underaccrual/(overaccrual)		
Section 9010 fee		
Change in nonadmitted assets	213,865	1.380
Meals and entertainment		
Change in valuation allowance		
Other, including expiration of charitable contribution c/f		
Establish DTA for accrued expenses		
Fines and Penalties		
Rounding		
Total	<u>\$ 3,467,473</u>	<u>22.380 %</u>
	03/31/2026	Effective Tax Rate
Federal income taxed incurred [expense/(benefit)]	\$ 3,135,606	20.238 %
Tax on capital gains		
Change in net deferred income tax [charge/(benefit)]	331,865	2.142
Total statutory income taxes	<u>\$ 3,467,471</u>	<u>22.380 %</u>

E. Operating loss and tax credit carryforwards

At March 31, 2026 the Company had \$0 of net operating loss carryforwards and \$1,754,380 of capital loss carryforwards which begin to expire in 2027.

- (1) Unused loss carryforwards available - None
- (2) Income tax expense available for recoupment

The following is income tax expense for 2026 and 2025 that is available for recoupment in the event of future net losses:

Notes to the Financial Statements

9. Income Taxes (Continued)

	Total
2024.....	\$
2025.....
2026.....

(3) Deposits admitted under IRS Code Section 6603 - None

The aggregate amount of deposits reported as admitted assets under Section 6603 of the Internal Revenue Service (IRS) Code was \$0 as of March 31, 2026.

F. Consolidated federal income tax return

(1) The Company's federal income tax return is consolidated with the following entities:

- Essence Group Holdings Corporation (EGHC) (Parent)
- Lumeris Holdings, LLC

(2) The method of allocation among companies is subject to a written agreement, approved by the Board of Directors, whereby allocation is based on Internal Revenue Code Section 1552(a)(2). Intercompany tax balances are settled monthly.

G. Federal or foreign income tax loss contingencies - None

H. Repatriation Transition Tax (RTT) - None

I. Alternative Minimum Tax (AMT) Credit

At March 31, 2026 the Company had \$0 of Alternative Minimum Tax (AMT) credits.

10. Information Concerning Parent, Subsidiaries, Affiliates and Other Related Parties

A. The company issued capital contributions to Essence Healthcare PPO, a wholly owned subsidiary in the first quarter of 2024 of \$9,300,000, in the second quarter of \$7,000,000, in the third quarter of \$6,100,000, and in the fourth quarter of \$7,400,000.

Essence Healthcare of Ohio, Inc., a wholly owned subsidiary, ceased operations as of December 31, 2025.

Essence Healthcare of Georgia, Inc., a wholly owned subsidiary, ceased operations as of December 31, 2023 and completed runout operations in 2025. The company will complete dissolution activities during 2026.

The Company's parent, LGHC, contributed \$9,100,000, \$13,000,000 and \$5,700,000, respectively, on September 30, 2024, December 31, 2024 and February 25, 2025, to the Company.

B. Detail of Related Party Transactions - None

C. Transactions with related party who are not reported on Schedule Y - No Significant Changes

D. Amounts Due from or to Related Parties

At March 31, 2026, the Company had a receivable from Essence Healthcare of GA, Inc., of \$1,651

At March 31, 2026, the Company had payables to Lumeris ARO St. Louis, LLC of \$5,916,320, \$2,143,819 to Lumeris Health Outcomes, LLC, \$43,121 to Essence Healthcare of OH, Inc., \$2,226,846 to Lumeris Group Holdings Corporation and \$1,923,782 to Essence Healthcare PPO, Inc.

E. Material management contracts

The Company and LGHC have entered into a Tax Allocation Agreement. The Company and its affiliate, Lumeris Healthcare Outcomes, LLC, have entered into an Intercompany Services Agreement. Pursuant to this agreement, Lumeris Healthcare Outcomes, LLC and the Company provide general and administrative services to each other on a cost-reimbursement basis. The Intercompany Services Agreement requires both parties to pay all invoices within 30 days of receipt

F. Guarantees or Contingencies - No Significant Changes

G. Nature of Relationships that Could Affect Operations - No Significant Changes

H. Amount Deducted for Investment in Upstream Company - No Significant Changes

I. Detail of Investments in Affiliates Greater Than 10% of Admitted Assets - No Significant Changes

J. Write-Down for Impairments of Investments in Subsidiary Controlled or Affiliated Companies - No Significant Changes

K. Foreign Subsidiary Value Using CARVM - No Significant Changes

L. Downstream Holding Company Value Using Look-Through Method - No Significant Changes

M. All SCA Investments - Not Applicable

N. Investment in Insurance SCAs - No Significant Changes

O. SCA and SSAP No. 48 Entity Loss Tracking - No Significant Changes

11. Debt - None

Notes to the Financial Statements

12. Retirement Plans, Deferred Compensation, Postemployment Benefits and Compensated Absences and Other Postretirement Benefit Plans

- A. Defined Benefit Plan - None
- B. Investment Policies and Strategies of Plan Assets - No Significant Changes
- C. Fair Value of Each Class of Plan Assets - No Significant Changes
- D. Expected Long-Term Rate of Return for the Plan Assets - No Significant Changes
- E. Defined Contribution Plans - No Significant Changes
- F. Multiemployer Plans - No Significant Changes
- G. Consolidated/Holding Company Plans

EHI maintains a 401(k) profit sharing plan through its affiliate, Lumeris Solutions Company, LLC. EHI has no legal obligation for benefits under the plan. Lumeris Solutions Company, LLC matches 50% of the first 8% of an active participant's contributions in the plan year. Total expense was \$1,716,601 and \$371,139 for December 31, 2025 and March 31, 2026, respectively.

- H. Postemployment Benefits and Compensated Absences - No Significant Changes
- I. Impact of Medicare Modernization Act on Postretirement Benefits (INT 04-17) - No Significant Changes

13. Capital and Surplus, Dividend Restrictions and Quasi-Reorganizations

- A. Outstanding Shares - No Significant Changes
- B. Dividend Rate of Preferred Stock - No Significant Changes
- C. Dividend Restrictions - No Significant Changes
- D. Ordinary Dividends - None
- E. Company Profits Paid as Ordinary Dividends - No Significant Changes
- F. Surplus Restrictions - No Significant Changes
- G. Surplus Advances - No Significant Changes
- H. Stock Held for Special Purposes - No Significant Changes
- I. Changes in Special Surplus Funds - No Significant Changes
- J. Unassigned Funds (Surplus) - No Significant Changes
- K. Company-Issued Surplus Debentures or Similar Obligations - None
- L. Impact of Any Restatement Due to Prior Quasi-Reorganizations - No Significant Changes
- M. Effective Date(s) of Quasi-Reorganizations in the Prior 10 Years - No Significant Changes

14. Liabilities, Contingencies and Assessments - No Significant Changes

15. Leases - No Significant Changes

16. Information About Financial Instruments With Off-Balance-Sheet Risk And Financial Instruments With Concentrations of Credit Risk - No Significant Changes

17. Sale, Transfer and Servicing of Financial Assets and Extinguishments of Liabilities

- A. Transfers of Receivables Reported as Sales - No Significant Changes
- B. Transfer and Servicing of Financial Assets - None
- C. Wash Sales - None

18. Gain or Loss to the Reporting Entity from Uninsured Plans and the Uninsured Portion of Partially Insured Plans - No Significant Changes

19. Direct Premium Written/Produced by Managing General Agents/Third Party Administrators - No Significant Changes

20. Fair Value Measurements

- A. Fair Value Measurement

The Company follows SSAP No. 100, Fair Value Measurements (SSAP No. 100), for the Company's financial assets and liabilities that are measured at fair value.

The Company's financial assets and liabilities carried at fair value have been classified, for disclosure purposes, based on a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The hierarchy gives the highest priority to fair values determined using unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to fair values determined using unobservable inputs (Level 3). An asset's or liability's classification is determined based on the lowest level input that is significant to its measurement.

For example, a Level 3 fair value measurement may include inputs that are both observable (Levels 1 and 2) and unobservable (Level3). The levels of the fair value hierarchy are as follows:

- Level 1: Inputs are unadjusted, quoted prices for identical assets or liabilities in active markets at the measurement date.
- Level 2: Inputs are other than quoted prices included in level 1 that are observable for the asset or liability through corroboration with market data at the measurement date.

Notes to the Financial Statements

20. Fair Value Measurements (Continued)

- Level 3: Inputs are unobservable and reflect management's best estimate of what market participants would use in pricing the asset or liability at the measurement date.

Fair value of actively traded fixed-income and equity securities is based on quoted market prices. Fair value of inactive traded fixed-income securities is based on quoted market prices of identical or similar securities based on observable inputs like interest rates using a market valuation approach is generally classified as Level 2. Investments measured based on the practical expedient being net asset value (NAV), based on the NAV of the fund as provided for in the audited financial statements and other fund reporting, are generally classified as Level 3.

(1) Fair value measurements at reporting date

Description for each class of asset or liability	Level 1	Level 2	Level 3	Net Asset Value (NAV)	Total
a. Assets at fair value					
Bonds	\$	\$ 499,796	\$	\$	\$ 499,796
Common Stock - Mutual Funds	983,000		23,243,750		24,226,750
Cash Equivalents - MM Mutual Funds	5,508,826				5,508,826
Total assets at fair value/NAV	\$ 6,491,826	\$ 499,796	\$ 23,243,750	\$	\$ 30,235,372
b. Liabilities at fair value					
Total liabilities at fair value	\$	\$	\$	\$	\$

(2) Fair value measurements in Level 3 of the fair value hierarchy - None

(3) The Company's policy for determining when transfers between levels are recognized is determined at the end of the reporting period.

(4) Inputs and techniques used for Level 2 and Level 3 fair values - None

(5) Derivatives - None

B. Other Fair Value Disclosures - None

C. Fair Values or NAV for All Financial Instruments

Type of Financial Instrument	Aggregate Fair Value	Admitted Assets	Level 1	Level 2	Level 3	Net Asset Value (NAV)	Not Practicable (Carrying Value)
Bonds	\$ 69,015,585	\$ 69,015,585	\$ 53,279,746	\$ 15,735,839	\$	\$	\$
Common Stock	24,226,750	20,285,856	983,000		23,243,750		
Cash Equivalents	5,508,826	5,508,826	5,508,826				

D. Not Practicable to Estimate Fair Value - None

E. Nature and Risk of Investments Reported at NAV - None

21. Other Items

On January 1, 2025, the Company entered into a reinsurance agreement with Canada Life, in which 40% of premiums and medical costs are ceded to the reinsurer. As of March 31, 2026, the Company ceded \$80,942,801 of premiums and \$73,345,915 of medical costs to Canada Life under this agreement. This is net \$14,265,601 of premiums and \$14,159,860 of medical costs assumed from Essence Healthcare PPO, Inc., with Essence Healthcare, Inc. acting as the pass through entity.

A. Unusual or Infrequent Items - None

B. Troubled Debt Restructuring - None

C. Other Disclosures - None

D. Business Interruption Insurance Recoveries - None

E. State and Federal Tax Credits - Not Applicable

F. Subprime-Mortgage-Related Risk Exposure - None

G. Retained Assets - None

H. Insurance-Linked Securities (ILS) Contracts - None

I. The Amount That Could Be Realized on Life Insurance Where the Reporting Entity is Owner and Beneficiary or Has Otherwise Obtained Rights to Control the Policy - None

22. Events Subsequent

1. Type I. – Recognized Subsequent Events

Subsequent events have been considered through May 15, 2026 for the statutory statement issued for March 31, 2026.

None

Type II. – Nonrecognized Subsequent Events

Subsequent events have been considered through May 15, 2026 for the statutory statement issued for March 31, 2026.

None

23. Reinsurance - No Significant Changes

24. Retrospectively Rated Contracts & Contracts Subject to Redetermination

A. Method Used to Estimate - No Significant Changes

Notes to the Financial Statements

24. Retrospectively Rated Contracts & Contracts Subject to Redetermination (Continued)

B. Method Used to Record - No Significant Changes

C. Amount and Percent of Net Retrospective Premiums

In 2025, the amount of premium subject to retrospective adjustment was \$90,661,173 which represents 19.07% of net premium written and earned for the year. In 2026 the amount of premium subject to retrospective adjustment was \$33,906,955, which represents 24.35% of net premium written and earned for the year.

D. Medical Loss Ratio Rebates Required Pursuant to the Public Health Service Act - No Significant Changes

E. Risk-Sharing Provisions of the Affordable Care Act (ACA) - None

25. Change in Incurred Claims and Claim Adjustment Expenses

A. Reasons for Changes in the Provision for Incurred Claim and Claim Adjustment Expenses Attributable to Insured Events of Prior Years

Reserves for claims and claim adjustment expenses as of December 31, 2025 were \$51,541,949. As of March 31, 2026, \$35,879,039 has been paid for incurred claims and claims adjustment expenses attributable to insured events of prior years. Reserves remaining for prior years are now \$17,682,335 as a result of re-estimation of unpaid claims and claim adjustment expenses. Therefore, there has been a \$(2,019,424) unfavorable prior-year development since December 31, 2025 to March 31, 2026. The change is generally the result of ongoing analysis of recent loss development trends. Original estimates are increased or decreased, as additional information becomes known regarding individual claims.

B. Significant Changes in Methodologies and Assumptions Used in Calculating the Liability for Unpaid Claims and Claim Adjustment Expenses - None

26. Intercompany Pooling Arrangements - No Significant Changes

27. Structured Settlements - No Significant Changes

28. Health Care Receivables - No Significant Changes

29. Participating Policies - No Significant Changes

30. Premium Deficiency Reserves - No Significant Changes

31. Anticipated Salvage and Subrogation - No Significant Changes

GENERAL INTERROGATORIES
PART 1 - COMMON INTERROGATORIES

GENERAL

- 1.1 Did the reporting entity experience any material transactions requiring the filing of Disclosure of Material Transactions with the State of Domicile, as required by the Model Act?..... NO.....
- 1.2 If yes, has the report been filed with the domiciliary state?..... NO.....
- 2.1 Has any change been made during the year of this statement in the charter, by-laws, articles of incorporation, or deed of settlement of the reporting entity?..... NO.....
- 2.2 If yes, date of change:.....
- 3.1 Is the reporting entity a member of an Insurance Holding Company System consisting of two or more affiliated persons, one or more of which is an insurer?..... YES.....
If yes, complete Schedule Y, Parts 1 and 1A.
- 3.2 Have there been any substantial changes in the organizational chart since the prior quarter end?..... NO.....
- 3.3 If the response to 3.2 is yes, provide a brief description of those changes.
- 3.4 Is the reporting entity publicly traded or a member of a publicly traded group?..... NO.....
- 3.5 If the response to 3.4 is yes, provide the CIK (Central Index Key) code issued by the SEC for the entity/group.....
- 4.1 Has the reporting entity been a party to a merger or consolidation during the period covered by this statement?..... NO.....
- 4.2 If yes, provide the name of entity, NAIC Company Code, and state of domicile (use two letter state abbreviation) for any entity that has ceased to exist as a result of the merger or consolidation.

1 Name of Entity	2 NAIC Company Code	3 State of Domicile

- 5. If the reporting entity is subject to a management agreement, including third-party administrator(s), managing general agent(s), attorney-in-fact, or similar agreement, have there been any significant changes regarding the terms of the agreement or principals involved?..... NO.....
If yes, attach an explanation.
- 6.1 State as of what date the latest financial examination of the reporting entity was made or is being made..... 12/31/2021.....
- 6.2 State the as of date that the latest financial examination report became available from either the state of domicile or the reporting entity. This date should be the date of the examined balance sheet and not the date the report was completed or released..... 12/31/2021.....
- 6.3 State as of what date the latest financial examination report became available to other states or the public from either the state of domicile or the reporting entity. This is the release date or completion date of the examination report and not the date of the examination (balance sheet date)..... 06/20/2023.....
- 6.4 By what department or departments?
Missouri Department of Insurance Financial Institutions and Professional Regulation
- 6.5 Have all financial statement adjustments within the latest financial examination report been accounted for in a subsequent financial statement filed with Departments?..... N/A.....
- 6.6 Have all of the recommendations within the latest financial examination report been complied with?..... N/A.....
- 7.1 Has this reporting entity had any Certificates of Authority, licenses or registrations (including corporate registration, if applicable) suspended or revoked by any governmental entity during the reporting period?..... NO.....
- 7.2 If yes, give full information
- 8.1 Is the company a subsidiary of a bank holding company regulated by the Federal Reserve Board?..... NO.....
- 8.2 If response to 8.1 is yes, please identify the name of the bank holding company.
- 8.3 Is the company affiliated with one or more banks, thrifts or securities firms?..... NO.....
- 8.4 If response to 8.3 is yes, please provide below the names and location (city and state of the main office) of any affiliates regulated by a federal regulatory services agency [i.e. the Federal Reserve Board (FRB), the Office of the Comptroller of the Currency (OCC), the Federal Deposit Insurance Corporation (FDIC) and the Securities Exchange Commission (SEC)] and identify the affiliates primary federal regulator.

1 Affiliate Name	2 Location (City, State)	3 FRB	4 OCC	5 FDIC	6 SEC

- 9.1 Are the senior officers (principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions) of the reporting entity subject to a code of ethics, which includes the following standards?..... YES.....
 - (a) Honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest between personal and professional relationships;
 - (b) Full, fair, accurate, timely and understandable disclosure in the periodic reports required to be filed by the reporting entity;
 - (c) Compliance with applicable governmental laws, rules and regulations;
 - (d) The prompt internal reporting of violations to an appropriate person or persons identified in the code; and
 - (e) Accountability for adherence to the code.
- 9.11 If the response to 9.1 is no, please explain:
- 9.2 Has the code of ethics for senior managers been amended?..... NO.....
- 9.21 If the response to 9.2 is yes, provide information related to amendment(s).
- 9.3 Have any provisions of the code of ethics been waived for any of the specified officers?..... NO.....
- 9.31 If the response to 9.3 is yes, provide the nature of any waiver(s).

GENERAL INTERROGATORIES
PART 1 - COMMON INTERROGATORIES

FINANCIAL

- 10.1 Does the reporting entity report any amounts due from parent, subsidiaries or affiliates on Page 2 of this statement?..... YES.....
- 10.2 If yes, indicate any amounts receivable from parent included in the Page 2 amount:..... \$..... -

INVESTMENT

- 11.1 Were any of the stocks, bonds, or other assets of the reporting entity loaned, placed under option agreement, or otherwise made available for use by another person? (Exclude securities under securities lending agreements.)..... NO.....
- 11.2 If yes, give full and complete information relating thereto:
12. Amount of real estate and mortgages held in other invested assets in Schedule BA:..... \$.....
- 13.1 Does the reporting entity have any investments in parent, subsidiaries and affiliates?..... YES.....
- 13.2 If yes, please complete the following:

	1	2
	Prior Year-End Book / Adjusted Carrying Value	Current Quarter Book / Adjusted Carrying Value
13.21 Bonds.....	\$.....	\$.....
13.22 Preferred Stock.....		
13.23 Common Stock.....	24,453,129	23,243,750
13.24 Short-Term Investments.....		
13.25 Mortgage Loans on Real Estate.....		
13.26 All Other.....		
13.27 Total Investment in Parent, Subsidiaries and Affiliates (Subtotal Lines 13.21 to 13.26).....	24,453,129	23,243,750
13.28 Total Investment in Parent included in Lines 13.21 to 13.26 above.....		

- 14.1 Has the reporting entity entered into any hedging transactions reported on Schedule DB?..... NO.....
- 14.2 If yes, has a comprehensive description of the hedging program been made available to the domiciliary state?..... NO.....
If no, attach a description with this statement.
15. For the reporting entity's security lending program, state the amount of the following as of the current statement date:
- 15.1 Total fair value of reinvested collateral assets reported on Schedule DL, Parts 1 and 2..... \$.....
- 15.2 Total book adjusted/carrying value of reinvested collateral assets reported on Schedule DL, Parts 1 and 2..... \$.....
- 15.3 Total payable for securities lending reported on the liability page..... \$.....

16. Excluding items in Schedule E - Part 3 - Special Deposits, real estate, mortgage loans and investments held physically in the reporting entity's offices, vaults or safety deposit boxes, were all stocks, bonds and other securities, owned throughout the current year held pursuant to a custodial agreement with a qualified bank or trust company in accordance with Section 1, III - General Examination Considerations, F. Outsourcing of Critical Functions, Custodial or Safekeeping Agreements of the NAIC *Financial Condition Examiners Handbook*?..... YES.....

- 16.1 For all agreements that comply with the requirements of the *Financial Condition Examiners Handbook*, complete the following:

1	2
Name of Custodian(s)	Custodian Address
Midwest Institutional Trust Services.....	10700 Research Drive, Suite 205, Wauwatosa, WI 53226-3460.....
BMO Harris Private Bank.....	13205 Manchester Road, St. Louis, MO 63131.....

- 16.2 For all agreements that do not comply with the requirements of the NAIC *Financial Condition Examiners Handbook*, provide the name, location and a complete explanation:

1	2	3
Name(s)	Location(s)	Complete Explanation(s)
.....

- 16.3 Have there been any changes, including name changes, in the custodian(s) identified in 16.1 during the current quarter?..... NO.....
- 16.4 If yes, give full and complete information relating thereto:

1	2	3	4
Old Custodian	New Custodian	Date of Change	Reason
.....

- 16.5 Investment management – Identify all investment advisors, investment managers, broker/dealers, including individuals that have the authority to make investment decisions on behalf of the reporting entity. This includes both primary and sub-advisors. For assets that are managed internally by employees of the reporting entity, note as such.

1	2
Name of Firm or Individual	Affiliation
BMO Harris Private Bank.....	U
AAM Insurance Investment Management.....	U

- 16.5097 For those firms/individuals listed in the table for Question 16.5, do any firms/individuals unaffiliated with the reporting entity (i.e., designated with a "U") manage more than 10% of the reporting entity's invested assets?..... YES.....
- 16.5098 For firms/individuals unaffiliated with the reporting entity (i.e., designated with a "U") listed in the table for Question 16.5, does the total assets under management aggregate to more than 50% of the reporting entity's invested assets?..... YES.....

GENERAL INTERROGATORIES
PART 1 - COMMON INTERROGATORIES

16.6 For those firms or individuals listed in the table for 16.5 with an affiliation code of "A" (affiliated) or "U" (unaffiliated), provide the information for the table below.

1	2	3	4
Central Registration Depository Number	Name of Firm or Individual	Registered With	Investment Management Agreement (IMA) Filed
160344.....	BMO Harris Private Bank.....	OCC.....	NO.....
109875.....	AAM Insurance Investment Management.....	SEC.....	NO.....

17.1 Have all the filing requirements of the *Purposes and Procedures Manual of the NAIC Investment Analysis Office* been followed?..... YES.....

17.2 If no, list exceptions:

18. By self-designating 5GI securities, the reporting entity is certifying the following elements for each self-designated 5GI security:

- a. Documentation necessary to permit a full credit analysis of the security does not exist or an NAIC CRP credit rating for an FE or PL security is not available.
- b. Issuer or obligor is current on all contracted interest and principal payments.
- c. The insurer has an actual expectation of ultimate payment of all contracted interest and principal.

Has the reporting entity self-designated 5GI securities per the criteria listed?..... NO.....

19. By self-designating PLGI securities, the reporting entity is certifying its compliance with the requirements as specified in the *Purposes and Procedures Manual of the NAIC Investment Analysis Office* (P&P Manual) for private letter rating (PLR) securities and the following elements of each self-designated PLGI security:

- a. The security was either:
 - i. issued prior to January 1, 2018 (which is exempt from PLR filing requirements pursuant to the P&P Manual), or
 - ii. issued from January 1, 2018 to December 31, 2021 and subject to a confidentiality agreement executed prior to January 1, 2022 which confidentiality agreement remains in force, for which an insurance company cannot provide a copy of a private letter rating rationale report to the SVO due to confidentiality or other contractual reasons ("waived submission PLR securities").
- b. The reporting entity is holding capital commensurate with the NAIC Designation and NAIC Designation Category reported for the security.
- c. The NAIC Designation and NAIC Designation Category were derived from the credit rating assigned by an NAIC CRP in its legal capacity as a NRSRO which is shown on a current private letter rating, dated during the financial statement year, held by the insurer and available for examination by state insurance regulators.
- d. Other than for waived submission PLR securities, defined above, on or after January 1, 2024 for any PLR securities issued on or after January 1, 2022, if the reporting entity is not permitted to share this private credit rating or the private rating letter rationale report of the PL security with the SVO, it certifies that it is reporting it as an NAIC 5.B GI and may not assign any other self-designation.

Has the reporting entity self-designated PLGI to securities, all of which meet the above requirement and as specified in the P&P Manual?..... NO.....

20. By assigning FE to a Schedule BA non-registered private fund, the reporting entity is certifying the following elements of each self-designated FE fund:

- a. The shares were purchased prior to January 1, 2019.
- b. The reporting entity is holding capital commensurate with the NAIC Designation reported for the security.
- c. The security had a public credit rating(s) with annual surveillance assigned by an NAIC CRP in its legal capacity as an NRSRO prior to January 1, 2019.
- d. The fund only or predominantly holds bonds in its portfolio.
- e. The current reported NAIC Designation was derived from the public credit rating(s) with annual surveillance assigned by an NAIC CRP in its legal capacity as an NRSRO.
- f. The public credit rating(s) with annual surveillance assigned by an NAIC CRP has not lapsed.

Has the reporting entity assigned FE to Schedule BA non-registered private funds that complied with the above criteria?..... NO.....

GENERAL INTERROGATORIES

PART 2 – HEALTH

1.	Operating Percentages:	
1.1	A&H loss percent.....	79.126 %
1.2	A&H cost containment percent.....	0.121 %
1.3	A&H expense percent excluding cost containment expenses.....	15.543 %
2.1	Do you act as a custodian for health savings accounts?.....	NO.....
2.2	If yes, please provide the amount of custodial funds held as of the reporting date.....	\$.....
2.3	Do you act as an administrator for health savings accounts?.....	NO.....
2.4	If yes, please provide the balance of the funds administered as of the reporting date.....	\$.....
3.	Is the reporting entity licensed or chartered, registered, qualified, eligible or writing business in at least two states?.....	YES.....
3.1	If no, does the reporting entity assume reinsurance business that covers risks residing in at least one state other than the state of domicile of the reporting entity?.....	

SCHEDULE S - CEDED REINSURANCE

Showing All New Reinsurance Treaties - Current Year to Date

1	2	3	4	5	6	7	8	9	10
NAIC Company Code	ID Number	Effective Date	Name of Reinsurer	Domiciliary Jurisdiction	Type of Reinsurance Ceded	Type of Business Ceded	Type of Reinsurer	Certified Reinsurer Rating (1 through 6)	Effective Date of Certified Reinsurer Rating
Accident & Health - Non-Affiliates									
..... 11835	04-1590940 01/01/2026	PartnerRe America Insurance Company..... DE SSL/I MR	Authorized
..... 80659	82-4533188 01/01/2025	Canada Life MI QA/G MR	Authorized

SCHEDULE T – PREMIUMS AND OTHER CONSIDERATIONS

Current Year to Date - Allocated by States and Territories

States, Etc.	1	Direct Business Only								
		2	3	4	5	6	7	8	9	10
	Active Status (a)	Accident & Health Premiums	Medicare Title XVIII	Medicaid Title XIX	CHIP Title XXI	Federal Employees Health Benefits Plan Premiums	Life & Annuity Premiums & Other Considerations	Property/Casualty Premiums	Total Columns 2 Through 8	Deposit-Type Contracts
1. Alabama	AL	N								
2. Alaska	AK	N								
3. Arizona	AZ	N								
4. Arkansas	AR	N								
5. California	CA	N								
6. Colorado	CO	N								
7. Connecticut	CT	N								
8. Delaware	DE	N								
9. District of Columbia	DC	N								
10. Florida	FL	N								
11. Georgia	GA	N								
12. Hawaii	HI	N								
13. Idaho	ID	N								
14. Illinois	IL	L							46,409,839	
15. Indiana	IN	L							462,290	
16. Iowa	IA	N								
17. Kansas	KS	N								
18. Kentucky	KY	L							2,979,262	
19. Louisiana	LA	N								
20. Maine	ME	N								
21. Maryland	MD	N								
22. Massachusetts	MA	N								
23. Michigan	MI	N								
24. Minnesota	MN	N								
25. Mississippi	MS	N								
26. Missouri	MO	L							170,497,821	
27. Montana	MT	N								
28. Nebraska	NE	N								
29. Nevada	NV	N								
30. New Hampshire	NH	N								
31. New Jersey	NJ	N								
32. New Mexico	NM	N								
33. New York	NY	N								
34. North Carolina	NC	N								
35. North Dakota	ND	N								
36. Ohio	OH	L								
37. Oklahoma	OK	N								
38. Oregon	OR	N								
39. Pennsylvania	PA	N								
40. Rhode Island	RI	N								
41. South Carolina	SC	N								
42. South Dakota	SD	N								
43. Tennessee	TN	N								
44. Texas	TX	L								
45. Utah	UT	N								
46. Vermont	VT	N								
47. Virginia	VA	N								
48. Washington	WA	L								
49. West Virginia	WV	N								
50. Wisconsin	WI	N								
51. Wyoming	WY	N								
52. American Samoa	AS	N								
53. Guam	GU	N								
54. Puerto Rico	PR	N								
55. U.S. Virgin Islands	VI	N								
56. Northern Mariana Islands	MP	N								
57. Canada	CAN	N								
58. Aggregate Other Alien	OT	XXX								
59. Subtotal	XXX								220,349,212	
60. Reporting entity contributions for employee benefits plans	XXX									
61. Total (direct business)	XXX								220,349,212	
Details of Write-Ins										
58001.	XXX									
58002.	XXX									
58003.	XXX									
58998. Summary of remaining write-ins for Line 58 from overflow page	XXX									
58999. Totals (Lines 58001 through 58003 plus 58998) (Line 58 above)	XXX									

(a) Active Status Counts

- 1. L – Licensed or Chartered - Licensed insurance carrier or domiciled RRG 7
- 2. R – Registered – Non-domiciled RRGs –
- 3. E – Eligible - Reporting entities eligible or approved to write surplus lines in the state –
- 4. Q – Qualified - Qualified or accredited reinsurer –
- 5. N – None of the above - Not allowed to write business in the state 50

SCHEDULE Y - INFORMATION CONCERNING ACTIVITIES OF INSURER MEMBERS OF A HOLDING COMPANY GROUP

PART 1 - ORGANIZATIONAL CHART

Entity Name		FEIN	State of Domicile	NAIC #
Lumeris Group Holdings Corporation		26-1245470	DE	
	Lumeris Holdings, LLC	80-0968618	DE	
	Lumeris Solutions Company, LLC	43-1861242	DE	
	Lumeris Healthcare Outcomes, LLC	47-2472489	NC	
	Lumeris ARO, LLC	26-3628710	MO	
	Forecast Health	82-3463296	FL	
	LHO of Florida, LLC	88-1789122	DE	
	Lumeris ARO St. Louis, LLC	88-1764234	DE	
	Lumeris ARO Arkansas, LLC	92-3102119	DE	
	Lumeris ARO Colorado, LLC	93-3879347	CO	
	Lumeris ARO NY IPA, LLC	99-0904611	NY	
	Lumeris ARO Illinois, LLC	93-3633636	IL	
	Lumeris ARO Ohio, LLC	93-1400012	DE	
	Lumeris ARO New Jersey, LLC	93-2085084	NJ	
	Lumeris ARO Oklahoma, LLC	93-1435438	DE	
	Provider's Choice LLC	99-2822679	MO	
	Medicare Partners MSSP II, LLC	99-3260508	DE	
	Medicare Partners MSSP III, LLC	99-3288876	DE	
	Medicare Partners MSSP IV, LLC	99-3374021	DE	
	Medicare Partners MSSP V, LLC	99-2822679	DE	
	Essence Plan Holdings, LLC	84-3677241	DE	
	Esse Health ACO, LLC (49%)	84-5172897	MO	
	Rancho Health Management, LLC (49%)	87-1943889	CA	
	Lumeris MSSP ACO, LLC	99-2894234	DE	
	Essence Healthcare of California, Inc.	46-4071746	CA	
	Essence Healthcare, Inc.	20-8185682	MO	11699
	Essence Healthcare of Ohio, Inc.	30-1295719	OH	17275
	Essence Healthcare PPO, Inc.	88-0718243	MO	17254

SCHEDULE Y - INFORMATION CONCERNING ACTIVITIES OF INSURER MEMBERS OF A HOLDING COMPANY GROUP

PART 1A - DETAILS OF ORGANIZATIONAL CHART COMPANY SYSTEM

1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16
Group Code	Group Name	NAIC Company Code	ID Number	Federal RSSD	CIK	Name of Securities Exchange if Publicly Traded (U.S. or International)	Names of Parent, Subsidiaries or Affiliates	Domiciliary Location	Relationship to Reporting Entity	Directly Controlled by (Name of Entity/Person)	Type of Control (Ownership, Board, Management, Attorney-in-Fact, Influence, Other)	If Control is Ownership, Provide Percentage	Ultimate Controlling Entity(ies) / Person(s)	Is an SCA Filing Required? (Yes/No)	*
4597	Lumeris Grp		26-3628710				Lumeris Healthcare Outcomes, LLC	MO	NIA	Lumeris Holdings LLC	Ownership	100.000	JDLinx, LLC	NO	
4597	Lumeris Grp		43-1861242				Lumeris Solutions Company, LLC	DE	NIA	Lumeris Holdings LLC	Ownership	100.000	JDLinx, LLC	NO	
4597	Lumeris Grp		80-0968618				Lumeris Holdings, LLC	DE	NIA	Lumeris Group Holdings Corporation	Ownership	100.000	JDLinx, LLC	NO	
4597	Lumeris Grp		26-1245470				Lumeris Group Holdings Corporation	DE	UDP	JDLinx, LLC	Ownership	60.790	JDLinx, LLC	NO	
4597	Lumeris Grp	11699	20-8185682				Essence Healthcare, Inc.	MO	RE	Lumeris Group Holdings Corporation	Ownership	100.000	JDLinx, LLC	NO	
4597	Lumeris Grp		47-2472489				Forecast Health Inc.	NC	NIA	Lumeris Solutions Company, LLC	Ownership	100.000	JDLinx, LLC	NO	
4597	Lumeris Grp		82-3463296				LHO of Florida, LLC	FL	NIA	Lumeris Healthcare Outcomes, LLC	Ownership	100.000	JDLinx, LLC	NO	
4597	Lumeris Grp		84-3677241				Essence Plan Holdings, LLC	DE	NIA	Lumeris Group Holdings Corporation	Ownership	100.000	JDLinx, LLC	NO	
4597	Lumeris Grp		84-5172897				Esse Health ACO, LLC	MO	NIA	Essence Plan Holdings, LLC	Ownership	49.000	JDLinx, LLC	NO	
4597	Lumeris Grp		87-1943889				Rancho Health Management, LLC	CA	NIA	Essence Plan Holdings, LLC	Ownership	49.000	JDLinx, LLC	NO	
4597	Lumeris Grp		99-2894234				Lumeris MSSP ACO, LLC	DE	NIA	Essence Plan Holdings, LLC	Ownership	100.000	JDLinx, LLC	NO	
4597	Lumeris Grp		46-4071746				Essence Healthcare of California, Inc.	CA	NIA	Essence Plan Holdings, LLC	Ownership	100.000	JDLinx, LLC	NO	
4597	Lumeris Grp	17254	88-0718243				Essence Healthcare PPO, Inc.	MO	DS	Essence Healthcare, Inc.	Ownership	100.000	JDLinx, LLC	NO	
4597	Lumeris Grp	17275	30-1295719				Essence Healthcare of Ohio, Inc.	OH	DS	Essence Healthcare, Inc.	Ownership	100.000	JDLinx, LLC	NO	
4597	Lumeris Grp		88-1789122				Lumeris ARO, LLC	DE	NIA	Lumeris Holdings LLC	Ownership	100.000	JDLinx, LLC	NO	
4597	Lumeris Grp		88-1764234				Lumeris ARO St. Louis, LLC	DE	NIA	Lumeris ARO, LLC	Ownership	100.000	JDLinx, LLC	NO	
4597	Lumeris Grp		92-3102119				Lumeris ARO Arkansas, LLC	DE	NIA	Lumeris ARO, LLC	Ownership	100.000	JDLinx, LLC	NO	
4597	Lumeris Grp		93-1400012				Lumeris ARO Ohio, LLC	DE	NIA	Lumeris ARO, LLC	Ownership	100.000	JDLinx, LLC	NO	
4597	Lumeris Grp		93-1435438				Lumeris ARO Oklahoma, LLC	DE	NIA	Lumeris ARO, LLC	Ownership	100.000	JDLinx, LLC	NO	
4597	Lumeris Grp		93-2085084				Lumeris ARO New Jersey, LLC	NJ	NIA	Lumeris ARO, LLC	Ownership	100.000	JDLinx, LLC	NO	
4597	Lumeris Grp		98-0904611				Lumeris ARO NY IPA, LLC	NY	NIA	Lumeris ARO, LLC	Ownership	100.000	JDLinx, LLC	NO	
4597	Lumeris Grp		93-3633636				Lumeris ARO Illinois, LLC	IL	NIA	Lumeris ARO, LLC	Ownership	100.000	JDLinx, LLC	NO	
4597	Lumeris Grp		93-3879347				Lumeris ARO Colorado, LLC	CO	NIA	Lumeris ARO, LLC	Ownership	100.000	JDLinx, LLC	NO	
4597	Lumeris Grp		99-2822679				Provider's Choice, LLC	MO	NIA	Lumeris Holdings LLC	Ownership	100.000	JDLinx, LLC	NO	
4597	Lumeris Grp		99-3260508				Medicare Partners MSSP II, LLC	DE	NIA	Lumeris Holdings LLC	Ownership	100.000	JDLinx, LLC	NO	
4597	Lumeris Grp		99-3266090				Medicare Partners MSSP III, LLC	DE	NIA	Lumeris Holdings LLC	Ownership	100.000	JDLinx, LLC	NO	
4597	Lumeris Grp		99-3288876				Medicare Partners MSSP IV, LLC	DE	NIA	Lumeris Holdings LLC	Ownership	100.000	JDLinx, LLC	NO	
4597	Lumeris Grp		99-3374021				Medicare Partners MSSP V, LLC	DE	NIA	Lumeris Holdings LLC	Ownership	100.000	JDLinx, LLC	NO	

Draft generated by Barry Almond on 4/21/2026 at 8:08 AM CDT

Asterisk	Explanation

SCHEDULE Y

PART 1A - DETAILS OF INSURANCE HOLDING COMPANY SYSTEM

1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16
Group Code	Group Name	NAIC Company Code	ID Number	Federal RSSD	CIK	Name of Securities Exchange if Publicly Traded (U.S. or International)	Names of Parent, Subsidiaries Or Affiliates	Domiciliary Location	Relationship to Reporting Entity	Directly Controlled by (Name of Entity/Person)	Type of Control (Ownership, Board, Management, Attorney-in-Fact, Influence, Other)	If Control is Ownership Provide Percentage	Ultimate Controlling Entity(ies) / Person(s)	Is an SCA Filing Required? (Yes/No)	*
4597	Lumeris Grp		26-3628710				Lumeris Healthcare Outcomes, LLC	MO	NIA	Lumeris Holdings LLC	Ownership	100.0	JDLinx, LLC	NO	
4597	Lumeris Grp		43-1861242				Lumeris Solutions Company, LLC	DE	NIA	Lumeris Holdings LLC	Ownership	100.0	JDLinx, LLC	NO	
4597	Lumeris Grp		80-0968618				Lumeris Holdings, LLC	DE	NIA	Lumeris Group Holdings Corporation	Ownership	100.0	JDLinx, LLC	NO	
4597	Lumeris Grp		26-1245470				Lumeris Group Holdings Corporation	DE	UDP	JDlinx, LLC	Ownership	60.8	JDLinx, LLC	NO	
4597	Lumeris Grp	11699	20-8185682				Essence Healthcare, Inc.	MO	RE	Lumeris Group Holdings Corporation	Ownership	100.0	JDLinx, LLC	NO	
4597	Lumeris Grp		47-2472489				Forecast Health Inc.	NC	NIA	Lumeris Solutions Company, LLC	Ownership	100.0	JDLinx, LLC	NO	
4597	Lumeris Grp		82-3463296				LHO of Florida, LLC	FL	NIA	Lumeris Healthcare Outcomes, LLC	Ownership	100.0	JDLinx, LLC	NO	
4597	Lumeris Grp		84-3677241				Essence Plan Holdings, LLC	DE	NIA	Lumeris Group Holdings Corporation	Ownership	100.0	JDlinx, LLC	NO	
4597	Lumeris Grp		84-5172897				Esse Health ACO, LLC	MO	NIA	Essence Plan Holdings, LLC	Ownership	49.0	JDLinx, LLC	NO	
4597	Lumeris Grp		87-1943889				Rancho Health Management, LLC	CA	NIA	Essence Plan Holdings, LLC	Ownership	49.0	JDLinx, LLC	NO	
4597	Lumeris Grp		99-2894234				Lumeris MSSP ACO, LLC	DE	NIA	Essence Plan Holdings, LLC	Ownership	100.0	JDLinx, LLC	NO	
4597	Lumeris Grp		46-4071746				Essence Healthcare of California, Inc.	CA	NIA	Essence Plan Holdings, LLC	Ownership	100.0	JDLinx, LLC	NO	
4597	Lumeris Grp	17254	88-0718243				Essence Healthcare PPO, Inc.	MO	DS	Essence Healthcare, Inc.	Ownership	100.0	JDLinx, LLC	NO	
4597	Lumeris Grp	17275	30-1295719				Essence Healthcare of Ohio, Inc.	OH	DS	Essence Healthcare, Inc.	Ownership	100.0	JDlinx, LLC	NO	
4597	Lumeris Grp		88-1789122				Lumeris ARO, LLC	DE	NIA	Lumeris Holdings LLC	Ownership	100.0	JDLinx, LLC	NO	
4597	Lumeris Grp		88-1764234				Lumeris ARO St. Louis, LLC	DE	NIA	Lumeris ARO, LLC	Ownership	100.0	JDLinx, LLC	NO	
4597	Lumeris Grp		92-3102119				Lumeris ARO Arkansas, LLC	DE	NIA	Lumeris ARO, LLC	Ownership	100.0	JDLinx, LLC	NO	
4597	Lumeris Grp		93-1400012				Lumeris ARO Ohio, LLC	DE	NIA	Lumeris ARO, LLC	Ownership	100.0	JDLinx, LLC	NO	
4597	Lumeris Grp		93-1435438				Lumeris ARO Oklahoma, LLC	DE	NIA	Lumeris ARO, LLC	Ownership	100.0	JDLinx, LLC	NO	
4597	Lumeris Grp		93-2085084				Lumeris ARO New Jersey, LLC	NJ	NIA	Lumeris ARO, LLC	Ownership	100.0	JDLinx, LLC	NO	
4597	Lumeris Grp		98-0904611				Lumeris ARO NY IPA, LLC	NY	NIA	Lumeris ARO, LLC	Ownership	100.0	JDLinx, LLC	NO	
4597	Lumeris Grp		93-3633636				Lumeris ARO Illinois, LLC	IL	NIA	Lumeris ARO, LLC	Ownership	100.0	JDLinx, LLC	NO	
4597	Lumeris Grp		93-3879347				Lumeris ARO Colorado, LLC	CO	NIA	Lumeris ARO, LLC	Ownership	100.0	JDLinx, LLC	NO	
4597	Lumeris Grp		99-2822679				Provider's Choice, LLC	MO	NIA	Lumeris Holdings LLC	Ownership	100.0	JDLinx, LLC	NO	
4597	Lumeris Grp		99-3260508				Medicare Partners MSSP II, LLC	DE	NIA	Lumeris Holdings LLC	Ownership	100.0	JDLinx, LLC	NO	
4597	Lumeris Grp		99-3266090				Medicare Partners MSSP III, LLC	DE	NIA	Lumeris Holdings LLC	Ownership	100.0	JDLinx, LLC	NO	
4597	Lumeris Grp		99-3288876				Medicare Partners MSSP IV, LLC	DE	NIA	Lumeris Holdings LLC	Ownership	100.0	JDLinx, LLC	NO	
4597	Lumeris Grp		99-3374021				Medicare Partners MSSP V, LLC	DE	NIA	Lumeris Holdings LLC	Ownership	100.0	JDLinx, LLC	NO	

16

Asterisk	Explanation
----------	-------------

SUPPLEMENTAL EXHIBITS AND SCHEDULES INTERROGATORIES

The following supplemental reports are required to be filed as part of your statement filing. However, in the event that your company does not transact the type of business for which the special report must be filed, your response of **NO** to the specific interrogatory will be accepted in lieu of filing a "NONE" report and a bar code will be printed below. If the supplement is required of your company but is not being filed for whatever reason enter **SEE EXPLANATION** and provide an explanation following the interrogatory questions.

	Response
1. Will the Medicare Part D Coverage Supplement be filed with the state of domicile and the NAIC with this statement?.....	No.....

August Filing

2. Will the regulator-only (non-public) Communication of Internal Control Related Matters Noted in Audit be filed with the state of domicile and electronically with the NAIC (as a regulator-only non-public document) by August 1? The response for 1st and 3rd quarters should be N/A. A NO response resulting with a bar code is only appropriate in the 2nd quarter.....	N/A.....
---	----------

EXPLANATION:

1.
2.

BARCODES:

1. 
1 1 6 9 9 2 0 2 6 3 6 5 0 0 0 1

2.

OVERFLOW PAGE FOR WRITE-INS

SCHEDULE A – VERIFICATION

Real Estate

	1	2
	Year to Date	Prior Year Ended December 31
1. Book/adjusted carrying value, December 31 of prior year		
2. Cost of acquired:		
2.1 Actual cost at time of acquisition		
2.2 Additional investment made after acquisition		
3. Current year change in encumbrances		
4. Total gain (loss) on disposals		
5. Deduct amounts received on disposals		
6. Total foreign exchange change in book / adjusted carrying value		
7. Deduct current year's other-than-temporary impairment recognized		
8. Deduct current year's depreciation		
9. Book/adjusted carrying value at the end of current period (Lines 1+2+3+4-5+6-7-8)		
10. Deduct total nonadmitted amounts		
11. Statement value at end of current period (Line 9 minus Line 10)		

NONE

SCHEDULE B – VERIFICATION

Mortgage Loans

	1	2
	Year to Date	Prior Year Ended December 31
1. Book value/recorded investment excluding accrued interest, December 31 of prior year		
2. Cost of acquired:		
2.1 Actual cost at time of acquisition		
2.2 Additional investment made after acquisition		
3. Capitalized deferred interest and other		
4. Accrual of discount		
5. Unrealized valuation increase / (decrease)		
6. Total gain (loss) on disposals		
7. Deduct amounts received on disposals		
8. Deduct amortization of premium and mortgage interest points and commitment fees		
9. Total foreign exchange change in book value/recorded investment excluding accrued interest		
10. Deduct current year's other-than-temporary impairment recognized		
11. Book value/recorded investment excluding accrued interest at end of current period (Lines 1+2+3+4+5+6-7-8+9-10)		
12. Total valuation allowance		
13. Subtotal (Line 11 plus Line 12)		
14. Deduct total nonadmitted amounts		
15. Statement value at end of current period (Line 13 minus Line 14)		

NONE

SCHEDULE BA - VERIFICATION

Other Long-Term Invested Assets

	1	2
	Year to Date	Prior Year Ended December 31
1. Book/adjusted carrying value, December 31 of prior year		
2. Cost of acquired:		
2.1 Actual cost at time of acquisition		
2.2 Additional investment made after acquisition		
3. Capitalized deferred interest and other		
4. Accrual of discount		
5. Unrealized valuation increase / (decrease)		
6. Total gain (loss) on disposals		
7. Deduct amounts received on disposals		
8. Deduct amortization of premium, depreciation and proportional amortization		
9. Total foreign exchange change in book / adjusted carrying value		
10. Deduct current year's other-than-temporary impairment recognized		
11. Book/adjusted carrying value at end of current period (Lines 1+2+3+4+5+6-7-8+9-10)		
12. Deduct total nonadmitted amounts		
13. Statement value at end of current period (Line 11 minus Line 12)		

NONE

SCHEDULE D - VERIFICATION

Bonds and Stocks

	1	2
	Year to Date	Prior Year Ended December 31
1. Book/adjusted carrying value of bonds and stocks, December 31 of prior year	94,320,848	138,746,609
2. Cost of bonds and stocks acquired	682,792	
3. Accrual of discount	11,860	70,678
4. Unrealized valuation increase / (decrease)	(1,210,379)	(5,397,189)
5. Total gain (loss) on disposals	(3,520)	(992,759)
6. Deduct consideration for bonds and stocks disposed of	529,795	37,986,462
7. Deduct amortization of premium	29,470	147,069
8. Total foreign exchange change in book / adjusted carrying value		
9. Deduct current year's other-than-temporary impairment recognized		
10. Total investment income recognized as a result of prepayment penalties and/or acceleration fees		27,040
11. Book/adjusted carrying value at end of current period (Lines 1+2+3+4+5-6-7+8-9+10)	93,242,336	94,320,848
12. Deduct total nonadmitted amounts	3,940,894	3,940,894
13. Statement value at end of current period (Line 11 minus Line 12)	89,301,442	90,379,954

SCHEDULE D – PART 1B

Showing the Acquisitions, Dispositions and Non-Trading Activity
During the Current Quarter for all Bonds and Preferred Stock by NAIC Designation

NAIC Designation	1 Book / Adjusted Carrying Value Beginning of Current Quarter	2 Acquisitions During Current Quarter	3 Dispositions During Current Quarter	4 Non-Trading Activity During Current Quarter	5 Book / Adjusted Carrying Value End of First Quarter	6 Book / Adjusted Carrying Value End of Second Quarter	7 Book / Adjusted Carrying Value End of Third Quarter	8 Book / Adjusted Carrying Value December 31 Prior Year
Issuer Credit Obligations (ICO)								
1. NAIC 1 (a)	33,214,165	682,792	6,118	341,134	34,231,973			33,214,165
2. NAIC 2 (a)	15,736,839			(351,698)	15,385,141			15,736,839
3. NAIC 3 (a)								
4. NAIC 4 (a)								
5. NAIC 5 (a)								
6. NAIC 6 (a)								
7. Total ICO	48,951,004	682,792	6,118	(10,564)	49,617,114			48,951,004
Asset-Backed Securities (ABS)								
8. NAIC 1	19,932,714		527,197	(7,045)	19,398,471			19,932,714
9. NAIC 2								
10. NAIC 3								
11. NAIC 4								
12. NAIC 5								
13. NAIC 6								
14. Total ABS	19,932,714		527,197	(7,045)	19,398,471			19,932,714
Preferred Stock								
15. NAIC 1								
16. NAIC 2								
17. NAIC 3								
18. NAIC 4								
19. NAIC 5								
20. NAIC 6								
21. Total Preferred Stock								
22. Total ICO, ABS, & Preferred Stock	68,883,718	682,792	533,316	(17,609)	69,015,585			68,883,718

(a) Book/Adjusted Carrying Value column for the end of the current reporting period includes the following amount of short-term and cash equivalent bonds by NAIC designation:
NAIC 1 \$; NAIC 2 \$; NAIC 3 \$; NAIC 4 \$; NAIC 5 \$; NAIC 6 \$

SCHEDULE DA - PART 1
Short-Term Investments

	1	2	3	4	5
	Book / Adjusted Carrying Value	Par Value	Actual Cost	Interest Collected Year To Date	Paid for Accrued Interest Year To Date
7709999999 Total	-	XXX			

NONE

SCHEDULE DA - VERIFICATION
Short-Term Investments

	1	2
	Year to Date	Prior Year Ended December 31
1. Book/adjusted carrying value, December 31 of prior year	-	-
2. Cost of short-term investments acquired		
3. Accrual of discount		
4. Unrealized valuation increase / (decrease)		
5. Total gain (loss) on disposals		
6. Deduct consideration received on disposals		
7. Deduct amortization of premium		
8. Total foreign exchange change in book / adjusted carrying value		
9. Deduct current year's other-than-temporary impairment recognized		
10. Book/adjusted carrying value at end of current period (Lines 1+2+3+4+5-6-7+8-9)	-	-
11. Deduct total nonadmitted amounts		
12. Statement value at end of current period (Line 10 minus Line 11)	-	-

NONE

(SI-04) Schedule DB - Part A - Verification - Options, Caps, Floors, Collars, Swaps and Forwards

NONE

(SI-04) Schedule DB - Part B - Verification - Futures Contracts

NONE

(SI-05) Schedule DB - Part C - Section 1

NONE

(SI-06) Schedule DB - Part C - Section 2

NONE

(SI-07) Schedule DB - Verification

NONE

SCHEDULE E – PART 2 – VERIFICATION
(Cash Equivalents)

	1	2
	Year to Date	Prior Year Ended December 31
1. Book/adjusted carrying value, December 31 of prior year.....	4,273,293	769,292
2. Cost of cash equivalents acquired.....	215,657,995	686,816,051
3. Accrual of discount.....		
4. Unrealized valuation increase / (decrease).....		
5. Total gain (loss) on disposals.....		
6. Deduct consideration received on disposals.....	214,422,462	683,312,050
7. Deduct amortization of premium.....		
8. Total foreign exchange change in book / adjusted carrying value.....		
9. Deduct current year's other-than-temporary impairment recognized.....		
10. Book/adjusted carrying value at end of current period (Lines 1+2+3+4+5-6-7+8-9).....	5,508,826	4,273,293
11. Deduct total nonadmitted amounts.....		
12. Statement value at end of current period (Line 10 minus Line 11).....	5,508,826	4,273,293

(E-01) Schedule A - Part 2

NONE

(E-01) Schedule A - Part 3

NONE

(E-02) Schedule B - Part 2

NONE

(E-02) Schedule B - Part 3

NONE

(E-03) Schedule BA - Part 2

NONE

(E-03) Schedule BA - Part 3

NONE

SCHEDULE D - PART 3

Show All Long-Term Bonds and Stocks Acquired During the Current Quarter

1 CUSIP Identification	2 Description	3 Date Acquired	4 Name of Vendor	5 Number of Shares of Stock	6 Actual Cost	7 Par Value	8 Paid for Accrued Interest and Dividends	9 NAIC Designation, NAIC Designation Modifier and SVO Administrative Symbol
Issuer Credit Obligations: U.S. Government Obligations (Exempt from RBC)								
91282C-CB-5	UNITED STATES TREASURY	02/25/2026	Unknown	XXX	682,792	682,792		1.A
0019999999 – Issuer Credit Obligations: U.S. Government Obligations (Exempt from RBC)					682,792	682,792		XXX
0489999999 – Subtotal - Issuer Obligations (Unaffiliated)					682,792	682,792		XXX
0509999997 – Subtotals - Issuer Credit Obligations - Part 3					682,792	682,792		XXX
0509999998 – Summary Item from Part 5 for Issuer Credit Obligations (N/A to Quarterly)					XXX	XXX	XXX	XXX
0509999999 – Subtotals - Issuer Credit Obligations					682,792	682,792		XXX
2009999999 – Subtotals - Issuer Credit Obligations and Asset-Backed Securities					682,792	682,792		XXX
6009999999 – Totals					682,792	XXX		XXX

SCHEDULE D - PART 4

Show All Long-Term Bonds and Stocks Sold, Redeemed or Otherwise Disposed of During the Current Quarter

1 CUSIP Identification	2 Description	3 Disposal Date	4 Name of Purchaser	5 Number of Shares of Stock	6 Consideration	7 Par Value	8 Actual Cost	9 Prior Year Book / Adjusted Carrying Value	Change in Book / Adjusted Carrying Value					15 Book / Adjusted Carrying Value at Disposal Date	16 Foreign Exchange Gain (Loss) on Disposal	17 Realized Gain (Loss) on Disposal	18 Total Gain (Loss) on Disposal	19 Bond Interest / Stock Dividends Received During Year	20 Stated Contractual Maturity Date	21 NAIC Designation, NAIC Designation Modifier and SVO Administrative Symbol	
									10 Unrealized Valuation Increase / (Decrease)	11 Current Year's (Amortization) / Accretion	12 Current Year's Other-Than- Temporary Impairment Recognized	13 Total Change in B. / A.C.V. (10+11-12)	14 Total Foreign Exchange Change in B./A.C.V.								
Issuer Credit Obligations: Corporate Bonds (Unaffiliated)																					
28249N-AA-9	EIG PEARL HOLDINGS SARL	02/28/2026	Paydown	XXX	6,091	6,091	6,125	6,118						6,118		(27)	(27)	108	08/31/2036	1.D FE	
0089999999 - Issuer Credit Obligations: Corporate Bonds (Unaffiliated)																					
					6,091	6,091	6,125	6,118						6,118		(27)	(27)	108	XXX	XXX	
0489999999 - Subtotal - Issuer Credit Obligations (Unaffiliated)																					
					6,091	6,091	6,125	6,118						6,118		(27)	(27)	108	XXX	XXX	
0509999997 - Subtotals - Issuer Credit Obligations - Part 4																					
					6,091	6,091	6,125	6,118						6,118		(27)	(27)	108	XXX	XXX	
0509999998 - Summary Item from Part 5 for Issuer Credit Obligations (N/A to Quarterly)																					
					XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
0509999999 - Subtotals - Issuer Credit Obligations																					
					6,091	6,091	6,125	6,118						6,118		(27)	(27)	108	XXX	XXX	
Asset-Backed Securities: Financial Asset-Backed - Self-Liquidating, Agency Residential Mortgage-Backed Securities - Guaranteed (Exempt from RBC)																					
38378T-AL-4	GNR 2013-071 LA - CMO/RMBS	03/01/2026	Paydown	XXX	731	731	747	745						745		(13)	(13)	4	10/20/2042	1.A	
38380B-4G-7	GNR 2016-160 AV - CMO/RMBS	03/01/2026	Paydown	XXX	16,202	16,202	16,430	16,265		(2)		(2)		16,263		(61)	(61)	81	10/20/2031	1.A	
1019999999 - Asset-Backed Securities: Financial Asset-Backed - Self-Liquidating, Agency Residential Mortgage-Backed Securities - Guaranteed (Exempt from RBC)																					
					16,933	16,933	17,176	17,010		(2)		(2)		17,008		(74)	(74)	85	XXX	XXX	
Asset-Backed Securities: Financial Asset-Backed - Self-Liquidating, Agency Commercial Mortgage-Backed Securities - Guaranteed (Exempt from RBC)																					
38379U-F7-6	GNR 16-105 VA - CMBS	03/01/2026	Paydown	XXX	19,566	19,566	19,578	19,559						19,559			7	7	65	05/16/2031	1.A
38379U-VC-7	GNR 2016-087 A - CMBS	03/01/2026	Paydown	XXX	3,826	3,826	3,892	3,830		(1)		(1)		3,829		(3)	(3)	14	09/16/2052	1.A	
38381E-UB-2	GNR 2022-013 AE - CMBS	03/01/2026	Paydown	XXX	6,164	6,164	6,064	6,106						6,107		57	57	15	09/16/2054	1.A	
1029999999 - Asset-Backed Securities: Financial Asset-Backed - Self-Liquidating, Agency Commercial Mortgage-Backed Securities - Guaranteed (Exempt from RBC)																					
					29,556	29,556	29,534	29,495		(1)		(1)		29,495			61	61	95	XXX	XXX
Asset-Backed Securities: Financial Asset-Backed - Self-Liquidating, Agency Residential Mortgage-Backed Securities - Not/Partially Guaranteed (Not Exempt from RBC)																					
3128MM-T9-4	FH G18575 - RMBS	03/01/2026	Paydown	XXX	7,962	7,962	8,199	8,063		(1)		(1)		8,062		(99)	(99)	40	11/01/2030	1.A	
31306X-QQ-9	FH J20463 - RMBS	03/01/2026	Paydown	XXX	3,194	3,194	3,309	3,214		(1)		(1)		3,213		(19)	(19)	13	09/01/2027	1.A	
3132D5-6B-3	FH SB8066 - RMBS	03/01/2026	Paydown	XXX	10,289	10,289	10,545	10,496		(1)		(1)		10,495		(205)	(205)	25	08/01/2035	1.A	
3132D5-6C-1	FH SB8067 - RMBS	03/01/2026	Paydown	XXX	14,074	14,074	14,476	14,404		(2)		(2)		14,402		(328)	(328)	34	09/01/2035	1.A	
3132D5-6U-1	FH SB8083 - RMBS	03/01/2026	Paydown	XXX	16,809	16,809	17,300	17,167		(2)		(2)		17,165		(356)	(356)	42	01/01/2036	1.A	
3132DV-7B-5	FH SD8090 - RMBS	03/01/2026	Paydown	XXX	8,554	8,554	8,857	8,850		(1)		(1)		8,849		(296)	(296)	28	09/01/2050	1.A	
3133KN-D8-3	FH RA6427 - RMBS	03/01/2026	Paydown	XXX	3,908	3,908	3,435	3,484						3,484		424	424	17	12/01/2051	1.A	
3136AK-3W-1	FNR 2014-64 BH - CMO/RMBS	01/26/2026	Paydown	XXX	190	190	192	190						190					03/25/2044	1.A	
3136AK-4D-2	FNR 2014-64 LV - CMO/RMBS	03/01/2026	Paydown	XXX	6,376	6,376	6,708	6,421		(2)		(2)		6,418		(43)	(43)	32	11/25/2027	1.A	
3136AP-EE-8	FNR 2015-47 GA - CMO/RMBS	03/01/2026	Paydown	XXX	1,823	1,823	1,839	1,829						1,829		(6)	(6)	11	06/25/2044	1.A	
3136AQ-7G-9	FNR 2016-10 LD - CMO/RMBS	03/01/2026	Paydown	XXX	2,306	2,306	2,405	2,311		(1)		(1)		2,310		(4)	(4)	12	10/25/2043	1.A	
3136AQ-K8-2	FNR 2015-94 LD - CMO/RMBS	03/01/2026	Paydown	XXX	4,493	4,493	4,693	4,544		(3)		(3)		4,541		(47)	(47)	27	08/25/2043	1.A	
3136BB-GK-2	FNR 2020-054 VC - CMO/RMBS	03/01/2026	Paydown	XXX	21,619	21,619	22,565	22,116		(7)		(7)		22,109		(490)	(490)	72	02/25/2032	1.A	
3137AY-YA-3	FHR 4170 PE - CMO/RMBS	03/01/2026	Paydown	XXX	3,937	3,937	3,988	3,956						3,956		(18)	(18)	15	01/15/2033	1.A	
3137B6-AY-7	FHR 4272 DC - CMO/RMBS	03/01/2026	Paydown	XXX	1,932	1,932	1,943	1,942						1,942		(9)	(9)	11	04/15/2043	1.A	
3138AW-3K-7	FN AJ5301 - RMBS	03/01/2026	Paydown	XXX	3,503	3,503	3,777	3,751		(1)		(1)		3,750		(247)	(247)	21	11/01/2041	1.A	
3138WA-VT-1	FN AS1525 - RMBS	03/01/2026	Paydown	XXX	5,768	5,768	5,932	5,813		(1)		(1)		5,812		(44)	(44)	29	01/01/2029	1.A	
3138WE-RN-1	FN AS4992 - RMBS	03/01/2026	Paydown	XXX	1,308	1,308	1,355	1,356						1,356		(49)	(49)	8	05/01/2045	1.A	
3138WE-U6-4	FN AS5104 - RMBS	03/01/2026	Paydown	XXX	3,561	3,561	3,652	3,652						3,652		(91)	(91)	21	06/01/2045	1.A	
3138WH-KE-1	FN AS7492 - RMBS	03/01/2026	Paydown	XXX	317	317	331	341						341		(25)	(25)	2	07/01/2046	1.A	
3140X9-S6-3	FN FM5940 - RMBS	03/01/2026	Paydown	XXX	15,502	15,502	16,066	15,986		(1)		(1)		15,984		(483)	(483)	63	02/01/2051	1.A	
31418C-S5-4	FN MA3239 - RMBS	03/01/2026	Paydown	XXX	1,231	1,231	1,280	1,328						1,328		(96)	(96)	8	01/01/2048	1.A	
31418D-SL-7	FN MA4122 - RMBS	03/01/2026	Paydown	XXX	14,941	14,941	15,296	15,215		(2)		(2)		15,213		(272)	(272)	36	09/01/2035	1.A	
31418D-SM-5	FN MA4123 - RMBS	03/01/2026	Paydown	XXX	13,577	13,577	14,154	14,076		(4)		(4)		14,072		(495)	(495)	45	09/01/2035	1.A	
31418D-W4-0	FN MA4266 - RMBS	03/01/2026	Paydown	XXX	13,391	13,391	13,665	13,603		(1)		(1)		13,602		(212)	(212)	33	02/01/2041	1.A	
1039999999 - Asset-Backed Securities: Financial Asset-Backed - Self-Liquidating, Agency Residential Mortgage-Backed Securities - Not/Partially Guaranteed (Not Exempt from RBC)																					
					180,564	180,564	185,961	184,109		(34)		(34)		184,075		(3,511)	(3,511)	645	XXX	XXX	
Asset-Backed Securities: Financial Asset-Backed - Self-Liquidating, Non-Agency Commercial Mortgage-Backed Securities (Unaffiliated)																					
06540L-AW-7	BANK 2021-BNK37 A1 - CMBS	03/01/2026	Paydown	XXX	67,733	67,733	67,733	67,706		(1)		(1)		67,706			27	27	137	11/18/2064	1.A FE
46644A-BF-8	JPMBB 2015-C27 A4 - CMBS	02/01/2026	Paydown	XXX	2,600	2,600	2,791	2,600						2,600				10	02/18/2048	1.C FE	
1079999999 - Asset-Backed Securities: Financial Asset-Backed - Self-Liquidating, Non-Agency Commercial Mortgage-Backed Securities (Unaffiliated)																					
					70,333	70,333	70,524	70,306		(1)		(1)		70,306			27	27	147	XXX	XXX
Asset-Backed Securities: Financial Asset-Backed - Self-Liquidating, Other Financial Asset-Backed Securities - Self-Liquidating (Unaffiliated)																					
12530M-AE-5	SORT 2021-1 A1 - ABS	03/15/2026	Paydown	XXX	4,757	4,757	4,544	4,745						4,752			5	5	8	03/15/2061	1.E FE
1119999999 - Asset-Backed Securities: Financial Asset-Backed - Self-Liquidating, Other Financial Asset-Backed Securities - Self-Liquidating (Unaffiliated)																					
					4,757	4,757	4,544	4,745						4,752			5	5	8	XXX	XXX
Asset-Backed Securities: Non-Financial Asset-Backed Securities - Practical Expedient, Other Non-Financial Asset-Backed Securities - Practical Expedient (Unaffiliated)																					
26444B-AA-2	DUK A A1 - ABS	01/01/2026	Paydown	XXX	79,032	79,032	79,032	79,032						79,032				512	07/01/2028	1.A FE	
54627R-AL-4	LASGOV 22A A1 - ABS	02/01/2026	Paydown	XXX	121,502	121,502	121,502	121,502						121,502				2,196	02/01/2029	1.A FE	
88240T-AA-9	ERCOTT 2022 A1 - ABS	02/01/2026	Paydown	XXX	21,027	21,027	21,027	21,028						21,028		(1)	(1)	448	08/01/2036	1.A FE	

F05

SCHEDULE D - PART 4

Show All Long-Term Bonds and Stocks Sold, Redeemed or Otherwise Disposed of During the Current Quarter

1 CUSIP Identification	2 Description	3 Disposal Date	4 Name of Purchaser	5 Number of Shares of Stock	6 Consideration	7 Par Value	8 Actual Cost	9 Prior Year Book / Adjusted Carrying Value	Change in Book / Adjusted Carrying Value					15 Book / Adjusted Carrying Value at Disposal Date	16 Foreign Exchange Gain (Loss) on Disposal	17 Realized Gain (Loss) on Disposal	18 Total Gain (Loss) on Disposal	19 Bond Interest / Stock Dividends Received During Year	20 Stated Contractual Maturity Date	21 NAIC Designation, NAIC Designation Modifier and SVO Administrative Symbol	
									10 Unrealized Valuation Increase / (Decrease)	11 Current Year's (Amortization) / Accretion	12 Current Year's Other-Than- Temporary Impairment Recognized	13 Total Change in B. / A.C.V. (10+11-12)	14 Total Foreign Exchange Change in B./A.C.V.								
1539999999	Asset-Backed Securities: Non-Financial Asset-Backed Securities - Practical Expedient, Other Non-Financial Asset-Backed Securities - Practical Expedient (Unaffiliated)				221,561	221,561	221,561	221,562		-			-		221,562		(1)	(1)	3,156	XXX	XXX
1889999999	Subtotal - Asset-Backed Securities (Unaffiliated)				523,704	523,704	529,300	527,228		(30)			(30)		527,197		(3,493)	(3,493)	4,137	XXX	XXX
1909999997	Subtotals - Asset-Backed Securities - Part 4				523,704	523,704	529,300	527,228		(30)			(30)		527,197		(3,493)	(3,493)	4,137	XXX	XXX
1909999998	Summary Item from Part 5 for Asset-Backed Securities (N/A to Quarterly)				XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX
1909999999	Subtotals - Asset-Backed Securities				523,704	523,704	529,300	527,228		(30)			(30)		527,197		(3,493)	(3,493)	4,137	XXX	XXX
2009999999	Subtotals - Issuer Credit Obligations and Asset-Backed Securities				529,795	529,795	535,426	533,346		(30)			(30)		533,316		(3,520)	(3,520)	4,245	XXX	XXX
6009999999	Totals				529,795	XXX	535,426	533,346		(30)			(30)		533,316		(3,520)	(3,520)	4,245	XXX	XXX

(E-06) Schedule DB - Part A - Section 1

NONE

(E-06) Schedule DB - Part A - Section 1 - Description of Hedged Risk(s)

NONE

(E-06) Schedule DB - Part A - Section 1 - Financial or Economic Impact of The Hedge at the End of the Reporting Period

NONE

(E-07) Schedule DB - Part B - Section 1

NONE

(E-07) Schedule DB - Part B - Section 1 - Broker Name

NONE

(E-07) Schedule DB - Part B - Section 1 - Description of Hedged Risk(s)

NONE

(E-07) Schedule DB - Part B - Section 1 - Financial or Economic Impact of The Hedge at the End of the Reporting Period

NONE

(E-08) Schedule DB - Part D - Section 1

NONE

(E-09) Schedule DB - Part D - Section 2 - Collateral Pledged By Reporting Entity

NONE

(E-09) Schedule DB - Part D - Section 2 - Collateral Pledged To Reporting Entity

NONE

(E-10) Schedule DB - Part E

NONE

(E-11) Schedule DL - Part 1

NONE

(E-12) Schedule DL - Part 2

NONE

SCHEDULE E - PART 1 - CASH

Month End Depository Balances

1 Depository	2 Restricted Asset Code	3 Rate of Interest	4 Amount of Interest Received During Current Quarter	5 Amount of Interest Accrued at Current Statement Date	Book Balance at End of Each Month During Current Quarter			9 *
					6 First Month	7 Second Month	8 Third Month	
BMO Harris Bank – Chicago, IL		2.477			43,869,669	42,028,729	43,179,423	XXX
0199998 – Deposits in depositories that do not exceed the allowable limit in any one depository (see Instructions) - open depositories								XXX
0199999 – Total open depositories					43,869,669	42,028,729	43,179,423	XXX
0299998 – Deposits in depositories that do not exceed the allowable limit in any one depository (see Instructions) - suspended depositories								XXX
0299999 – Total suspended depositories								XXX
0399999 – Total cash on deposit					43,869,669	42,028,729	43,179,423	XXX
0499999 – Cash in company's office					XXX	XXX		XXX
0599999 – Total					43,869,669	42,028,729	43,179,423	XXX

SCHEDULE E - PART 2 - CASH EQUIVALENTS

Show Investments Owned End of Current Quarter

1 CUSIP	2 Description	3 Restricted Asset Code	4 Date Acquired	5 Stated Rate of Interest	6 Maturity Date	7 Book / Adjusted Carrying Value	8 Amount of Interest Due and Accrued	9 Amount Received During Year
All Other Money Market Mutual Funds								
38141W-26-5	GOLDMAN:FS GOVT ADM		03/31/2026	3.300	XXX	5,128,541	63,196	37,375
60934N-10-4	FEDERATED HRMS GV O INST		03/31/2026	3.520	XXX	380,285		3,439
8309999999 – All Other Money Market Mutual Funds						5,508,826	63,196	40,814
8589999999 – Total Cash Equivalents (Unaffiliated)						5,508,826	63,196	40,814
8609999999 – Total cash equivalents						5,508,826	63,196	40,814